Phage compositions against Pseudomonas containing a CRISPR-CAS system and methods of use thereof
Patent Information
- Application Number
- JP2023527227
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-05-05
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 110,288, filed November 5, 2020, and U.S. Provisional Patent Application No. 63 / 184,728, filed May 5, 2021, both of which are incorporated herein by reference.
[0002] Sequence Listing This application has been submitted electronically in ASCII format and contains a Sequence Listing, which is incorporated herein by reference. The above ASCII copy, created on October 27, 2021, is named 53240-743_601_SL.txt and is 71,774 bytes in size. Summary of the Invention
[0003] In certain embodiments, disclosed herein are phage compositions comprising CRISPR-Cas systems and methods of using the same.
[0004] Certain embodiments disclosed herein include a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system comprising a CRISPR array comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array further comprises at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to one or more spacer sequences at either its 5' or 3' end. In some embodiments, the repeat sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the target nucleotide sequence comprises a coding sequence. In some embodiments, the target nucleotide sequence comprises a non-coding or intergenic sequence. In some embodiments, the target nucleotide sequence comprises all or a portion of a promoter sequence. In some embodiments, the promoter sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 1-11. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding strand of a transcribed region of an essential gene.In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the Cascade polypeptides form a Cascade complex of a type IA CRISPR-Cas system, a type IB CRISPR-Cas system, a type IC CRISPR-Cas system, a type ID CRISPR-Cas system, a type IE CRISPR-Cas system, or an IF CRISPR-Cas system. In some embodiments, the Cascade complex comprises (i) a Cas7 polypeptide, a Cas8a1 or Cas8a2 polypeptide, a Cas5 polypeptide, a Csa5 polypeptide, and a Cas6a polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity (a type IA CRISPR-Cas system), (ii) a Cas6b polypeptide, a Cas8b polypeptide, a Cas7 polypeptide, and a Cas5 polypeptide (a type IB CRISPR-Cas system), (iii) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide (a type IB CRISPR-Cas system), (iv) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity. (iv) Cas10d polypeptide, Csc2 polypeptide, Csc1 polypeptide, Cas6d polypeptide (ID type CRISPR-Cas system); (v) Cse1 polypeptide, Cse2 polypeptide, Cas7 polypeptide, Cas5 polypeptide, and Cas6e polypeptide (IE type CRISPR-Cas system); and (vi) Csy1 polypeptide, Csy2 polypeptide, Csy3 polypeptide, and Csy4 polypeptide (IF type CRISPR-Cas system).In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the nucleic acid sequence further comprises a promoter sequence. In some embodiments, the Pseudomonas species is killed by the lytic activity of the bacteriophage alone. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system alone. In some embodiments, the Pseudomonas species is killed by a combination of the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system independently of the lytic activity of the bacteriophage. In some embodiments, the activity of the CRISPR-Cas system complements or enhances the lytic activity of the bacteriophage. In some embodiments, the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system are synergistic. In some embodiments, the lytic activity of the bacteriophage, the activity of the CRISPR-Cas system, or both, is regulated by the concentration of the bacteriophage. In some embodiments, the bacteriophage infects multiple bacterial strains. In some embodiments, the bacteriophage is an obligate lytic bacteriophage. In some embodiments, the bacteriophage is a lysogenic bacteriophage that has been rendered lytic. In some embodiments, the lysogenic bacteriophage is rendered lytic by removal, replacement, or inactivation of a lysogenic gene.In some embodiments, the bacteriophage is selected from the group consisting of PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cysto virus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, and the like. In some embodiments, the bacteriophage is engineered from a bacteriophage that infects Pseudomonas. In some embodiments, the bacteriophage that infects Pseudomonas includes subtypes of wild-type Pbuna virus phages listed in Table 5A, which infect the target Pseudomonas as marked with a plus sign (+) (e.g., phage p1106 infects b002548).In some embodiments, the bacteriophage that infects Pseudomonas includes an engineered Pbuna virus phage subtype listed in Table 5A, which infects the target Pseudomonas as marked with a plus sign (+) (e.g., p1106e003 infects b002548). In some embodiments, the bacteriophage that infects Pseudomonas includes a wild-type Samuna virus phage subtype, an engineered Samuna virus phage subtype, wild-type PhiKZ virus, wild-type PhiKMV virus, or wild-type Bruynoghe virus, for example, as listed in Table 5B, which infects the target Pseudomonas as marked with a plus sign (+). As listed in Table 5A, the phage subtype of the wild-type Pbuna virus can be p1106, p1587, p1835, p2037, p2363, p2421, and / or pb1, while the phage subtype of the engineered Pbuna virus can be p1106e003, p1587e002, p1835e002, p2037e002, p2363e003, and / or p2421e002. As listed in Table 5B, the phage subtype of wild-type Samuna virus can be p1772, p2131, p2132, and / or p2973; the phage subtype of engineered Samuna virus can be pb1e002, p1772e005, p2131e002, p2132e002, and / or p2973e002; the phage subtype of wild-type PhiKZ virus can be p1194 and / or p4430; the phage subtype of wild-type PhiKMV virus can be p2167; and the phage subtype of wild-type Bruynoghe virus can be p1695 and p3278. In some embodiments, the bacteriophage that infects Pseudomonas is Nankoku virus. In some embodiments, the bacteriophage that infects Pseudomonas kills Pseudomonas. In some embodiments, bacteriophages that infect Pseudomonas do not infect Staphylococcus aureus.In some embodiments, bacteriophages that infect Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not infect Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that infect Pseudomonas do not infect Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not kill Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not infect Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not kill Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that kills Pseudomonas does not kill Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterobacter cloacae. In some embodiments, the bacteriophage that kills Pseudomonas. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Staphylococcus epidermidis. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the bacteriophage that kills Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the combination of bacteriophages infects Pseudomonas. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B. In some embodiments, the combination of bacteriophages kills Pseudomonas.As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B.
[0005] In some embodiments, a cocktail system is provided that includes one or more bacteriophages, including any one or more of p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the bacteriophage cocktail system used herein comprises one, two, three, four, five, six, or more selected from the group consisting of p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, and PB1. In some embodiments, the bacteriophage is a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a bacteriophage selected from p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, and PB1. In some embodiments, the bacteriophages in the bacteriophage cocktail system used herein are p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131 Contains any one, two, three, four, five, six, or more of: e002, p2131wt, p2132e002, p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt.In some embodiments, the bacteriophages in the bacteriophage cocktail system used herein are p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p2131wt, p2132e002, The bacteriophage cocktail system used herein includes a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the bacteriophage in the bacteriophage cocktail system used herein includes any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p1194, p4430, and p1695. In some embodiments, the nucleic acid sequence is inserted in place of or adjacent to a non-essential bacteriophage gene. In some embodiments, the bacteriophage is selected from the group consisting of p1106e003, p1835e002, p1772e005, and p2131e002. In some embodiments, the bacteriophage in the bacteriophage cocktail system used herein comprises any one or more of p1106e003, p1835e002, p1772e005, p2131e002, and p1194. In some embodiments, the bacteriophage in the bacteriophage cocktail system used herein comprises any one or more of p1106e003, p1835e002, p1772e005, p2131e002, and p4430. In some embodiments, the bacteriophages in the bacteriophage cocktail system used herein include any one or more of p1106e003, p1835e002, p1772e005, p2131e002, and p1695.In some embodiments, the bacteriophages in the bacteriophage cocktail system used herein include any one or more of ep1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the bacteriophages in the bacteriophage cocktail system used herein include any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695. In some embodiments, the bacteriophage cocktail system comprises bacteriophages of CK000512 (p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695).
[0006]
[0010] In certain embodiments, disclosed herein are pharmaceutical compositions comprising (a) a bacteriophage described herein and (b) a pharmaceutically acceptable excipient. In some embodiments, the bacteriophage is selected from PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimtre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, and Pbuna virus. In some embodiments, the pharmaceutical composition comprises at least six bacteriophages, wherein the bacteriophages are selected from among p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695 phages. In some embodiments, the pharmaceutical composition comprises at least six bacteriophages, wherein the bacteriophages in the bacteriophage cocktail system used herein include any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695. In some embodiments, the pharmaceutical composition is in the form of a tablet, liquid, syrup, oral formulation, intravenous formulation, intranasal formulation, ophthalmic formulation, otic formulation, subcutaneous formulation, inhalable respiratory formulation, suppository, lyophilized formulation, nebulizable formulation, and any combination thereof. In one embodiment, the pharmaceutical composition comprises p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695 in a nebulizable formulation for pulmonary delivery.
[0007] Disclosed herein in certain aspects is a method for killing Pseudomonas species, comprising introducing a nucleic acid sequence encoding a type I CRISPR-Cas system from a bacteriophage into a target bacterium, wherein the nucleic acid comprises a CRISPR array comprising one or more spacer sequences complementary to a target nucleotide sequence in the Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOS: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOS: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array further comprises at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to one or more spacer sequences at either its 5' or 3' end. In some embodiments, the repeat sequence comprises at least about 90% sequence identity to any one of SEQ ID NOS: 26-30. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the target nucleotide sequence comprises a coding sequence. In some embodiments, the target nucleotide sequence comprises a non-coding or intergenic sequence. In some embodiments, the target nucleotide sequence comprises all or a portion of a promoter sequence. In some embodiments, the promoter sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 1-11. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding strand of a transcribed region of an essential gene.In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the Cascade polypeptides form a Cascade complex of a type IA CRISPR-Cas system, a type IB CRISPR-Cas system, a type IC CRISPR-Cas system, a type ID CRISPR-Cas system, a type IE CRISPR-Cas system, or an IF CRISPR-Cas system. In some embodiments, the Cascade complex comprises (i) a Cas7 polypeptide, a Cas8a1 or Cas8a2 polypeptide, a Cas5 polypeptide, a Csa5 polypeptide, and a Cas6a polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity (a type IA CRISPR-Cas system), (ii) a Cas6b polypeptide, a Cas8b polypeptide, a Cas7 polypeptide, and a Cas5 polypeptide (a type IB CRISPR-Cas system), (iii) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide (a type IB CRISPR-Cas system), (iv) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity. (iv) Cas10d polypeptide, Csc2 polypeptide, Csc1 polypeptide, Cas6d polypeptide (ID type CRISPR-Cas system); (v) Cse1 polypeptide, Cse2 polypeptide, Cas7 polypeptide, Cas5 polypeptide, and Cas6e polypeptide (IE type CRISPR-Cas system); and (vi) Csy1 polypeptide, Csy2 polypeptide, Csy3 polypeptide, and Csy4 polypeptide (IF type CRISPR-Cas system).In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the nucleic acid sequence further comprises a promoter sequence. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system alone. In some embodiments, the Pseudomonas species is killed by a combination of the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system independently of the lytic activity of the bacteriophage. In some embodiments, the activity of the CRISPR-Cas system complements or enhances the lytic activity of the bacteriophage. In some embodiments, the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system are synergistic. In some embodiments, the lytic activity of the bacteriophage, the activity of the CRISPR-Cas system, or both, is regulated by the concentration of the bacteriophage. In some embodiments, the bacteriophage infects multiple bacterial strains. In some embodiments, the bacteriophage is an obligately lytic bacteriophage. In some embodiments, the bacteriophage is a lysogenic bacteriophage that has been rendered lytic. In some embodiments, the lysogenic bacteriophage is rendered lytic by removal, replacement, or inactivation of a lysogenic gene.In some embodiments, the bacteriophage comprises a bacteriophage of PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimatre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the bacteriophage is part of a bacteriophage cocktail. In some embodiments, the bacteriophage or bacteriophage cocktail comprises p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1, or two or more phages thereof. In some embodiments, the bacteriophage is a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a bacteriophage selected from p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, and PB1.In some embodiments, the bacteriophage or bacteriophage cocktail is selected from the group consisting of p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p21 31e002, p2131wt, p2132e002, p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the bacteriophage or bacteriophage cocktail is selected from the group consisting of p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p2131wt, p2132e002, p2132 In some embodiments, the mixed population of bacterial cells comprises a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to Pseudomonas sp.wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the nucleic acid sequence is inserted in place or adjacent to a non-essential bacteriophage gene. In some embodiments, the mixed population of bacterial cells comprises Pseudomonas sp. In some embodiments, the bacteriophage cocktail comprises p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the bacteriophage cocktail comprises p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695.
[0008] Disclosed herein in certain aspects are methods of treating a disease or disorder in an individual in need thereof, comprising administering to the individual a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system, the type I CRISPR-Cas system comprising a CRISPR array, a Cascade polypeptide comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array further comprises at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to the one or more spacer sequences at either its 5' or 3' end. In some embodiments, the repeat sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the target nucleotide sequence comprises a coding sequence. In some embodiments, the target nucleotide sequence comprises a non-coding or intergenic sequence. In some embodiments, the target nucleic acid sequence comprises all or a portion of a promoter sequence. In some embodiments, the promoter sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 1-11. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding strand of a transcribed region of an essential gene.In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the Cascade polypeptides form a Cascade complex of a type IA CRISPR-Cas system, a type IB CRISPR-Cas system, a type IC CRISPR-Cas system, a type ID CRISPR-Cas system, a type IE CRISPR-Cas system, or an IF CRISPR-Cas system. In some embodiments, the Cascade complex comprises (i) a Cas7 polypeptide, a Cas8a1 or Cas8a2 polypeptide, a Cas5 polypeptide, a Csa5 polypeptide, and a Cas6a polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity (a type IA CRISPR-Cas system), (ii) a Cas6b polypeptide, a Cas8b polypeptide, a Cas7 polypeptide, and a Cas5 polypeptide (a type IB CRISPR-Cas system), (iii) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide (a type IB CRISPR-Cas system), (iv) a Cas5d polypeptide, a Csa5 polypeptide, and a Cas6b polypeptide, wherein the Cas3 comprises a Cas3' polypeptide and a Cas3" polypeptide that do not have nuclease activity. (iv) Cas10d polypeptide, Csc2 polypeptide, Csc1 polypeptide, Cas6d polypeptide (ID type CRISPR-Cas system); (v) Cse1 polypeptide, Cse2 polypeptide, Cas7 polypeptide, Cas5 polypeptide, and Cas6e polypeptide (IE type CRISPR-Cas system); and (vi) Csy1 polypeptide, Csy2 polypeptide, Csy3 polypeptide, and Csy4 polypeptide (IF type CRISPR-Cas system).In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the nucleic acid sequence further comprises a promoter sequence. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system alone. In some embodiments, the Pseudomonas species is killed by a combination of the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system. In some embodiments, the Pseudomonas species is killed by the activity of the CRISPR-Cas system independently of the lytic activity of the bacteriophage. In some embodiments, the activity of the CRISPR-Cas system complements or enhances the lytic activity of the bacteriophage. In some embodiments, the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system are synergistic. In some embodiments, the lytic activity of the bacteriophage, the activity of the CRISPR-Cas system, or both, is regulated by the concentration of the bacteriophage. In some embodiments, the bacteriophage infects multiple bacterial strains. In some embodiments, the bacteriophage is an obligately lytic bacteriophage. In some embodiments, the bacteriophage is a lysogenic bacteriophage that has been rendered lytic. In some embodiments, the lysogenic bacteriophage is rendered lytic by removal, replacement, or inactivation of a lysogenic gene.In some embodiments, the bacteriophage comprises a PhiKZ virus, a PhiKMV virus, a Brunyoghe virus, a Samuna virus, a Nankoku virus, an Abidjan virus, a Baikal virus, a Beetre virus, a Casadaban virus, a Citex virus, a Cystovirus, a Detre virus, an El virus, a Holloway virus, a Kochitakasu virus, a Lituna virus, a Luzseptima virus, a Nipuna virus, a Pakpuna virus, a Pamex virus, a Paundecim virus, a Phitre virus, a Primolici virus, a Septimatre virus, a Stubbur virus, a Tertilici virus, a Yua virus, a Zicotria virus, or a Pbuna virus. In some embodiments, the bacteriophage is part of a bacteriophage cocktail. In some embodiments, the bacteriophage or bacteriophage cocktail comprises p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1, or two or more phages thereof. In some embodiments, the bacteriophage is a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a bacteriophage selected from p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, and PB1.In some embodiments, the bacteriophage or bacteriophage cocktail is selected from the group consisting of p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p21 31e002, p2131wt, p2132e002, p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the bacteriophage or bacteriophage cocktail is selected from the group consisting of p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p2131wt, p2132e002, p2132wt, p21 The method includes administering at least one bacteriophage type, including p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or a bacteriophage having at least 80%, at least 85%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the nucleic acid sequence is inserted in place or adjacent to a non-essential bacteriophage gene. In some embodiments, the method further comprises administering at least one additional bacteriophage type. In some embodiments, the method further comprises administering 2, 3, 4, 5, 6, 7, 8, 9, or 10 different bacteriophages. In some embodiments, the method further comprises administering at least six different bacteriophages.In some embodiments, the method further comprises administering at least six different bacteriophages, wherein the bacteriophages in the bacteriophage cocktail system used herein include any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the method further comprises administering at least six different bacteriophages, wherein the bacteriophages include p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is a Pseudomonas bacterial infection. In some embodiments, the bacterial infection is associated with cystic fibrosis. In some embodiments, the bacterial infection is associated with non-cystic fibrosis bronchiectasis. In some embodiments, the disease or condition is cystic fibrosis. In some embodiments, the disease or condition is non-cystic fibrosis bronchiectasis. In some embodiments, the bacterial infection is a Pseudomonas bacterial infection associated with cystic fibrosis. In some embodiments, the bacterial infection is a Pseudomonas bacterial infection associated with non-cystic fibrosis bronchiectasis. In some embodiments, the disease or condition is pneumonia. For example, the pneumonia is hospital-acquired pneumonia, ventilator-associated pneumonia, community-acquired pneumonia, or healthcare-associated pneumonia. In some embodiments, the disease or condition is a blood-system infection (BSI). In some embodiments, the Pseudomonas species causing the disease or condition is a drug-resistant Pseudomonas species. In some embodiments, the drug-resistant Pseudomonas species is resistant to at least one antibiotic. In some embodiments, the Pseudomonas species causing the disease or condition is a multidrug-resistant Pseudomonas species. In some embodiments, the multidrug-resistant Pseudomonas species is resistant to at least one antibiotic. In some embodiments, the antibiotic comprises a cephalosporin, a fluoroquinolone, a carbapenem, a colistin, an aminoglycoside, vancomycin, streptomycin, or methicillin. In some embodiments, the Pseudomonas species is Pseudomonas aeruginosa.In some embodiments, administration is intra-arterial, intravenous, intraurethral, intramuscular, or intravenous. The administration may be oral, subcutaneous, inhalation, topical, dermal, transdermal, oral mucosal, implanted, sublingual, buccal, rectal, vaginal, ocular, otic, nasal, or any combination thereof. In some embodiments, the method further comprises administering an additional therapy. In some embodiments, the additional therapy comprises tobramycin. In some embodiments, the individual is a mammal. In some embodiments, the additional therapy comprises a drug for improving airway function. In some embodiments, the additional therapy comprises a drug for reducing airway responsiveness. In some embodiments, the additional therapy comprises a drug for reducing airway inflammation. In some embodiments, the additional therapy comprises a bronchodilator. In some embodiments, the additional therapy comprises a drug for improving oxygen utilization. In some embodiments, the additional therapy comprises a drug for reducing airway germ cell hypersecretion. In some embodiments, the additional therapy comprises DNAse. In some embodiments, the additional therapy is saline. In some embodiments, the additional therapy is a therapy comprising a coughing practice, for example, used in the treatment of cystic fibrosis.
[0009] In certain aspects herein, a bacteriophage is disclosed that includes a CRISPR array comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide comprising Cas5, Cas8c, and Cas7, and a Cas3 polypeptide, and a nucleic acid sequence encoding a type I CRISPR-Cas system. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array further comprises at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to one or more spacer sequences at either its 5' or 3' end. In some embodiments, the repeat sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the target nucleotide sequence comprises a coding sequence. In some embodiments, the target nucleotide sequence comprises a non-coding or intergenic sequence. In some embodiments, the target nucleotide sequence comprises all or a portion of a promoter sequence. In some embodiments, the promoter sequence comprises at least about 90% sequence identity to any one of SEQ ID NOs: 1-11. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding strand of a transcribed region of an essential gene.In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the nucleic acid sequence further comprises a promoter sequence. In some embodiments, the Pseudomonas species is killed solely by the lytic activity of the bacteriophage. In some embodiments, the Pseudomonas species is killed solely by the activity of the CRISPR-Cas system. In some embodiments, Pseudomonas species are killed by a combination of the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system. In some embodiments, Pseudomonas species are killed by the activity of the CRISPR-Cas system independently of the lytic activity of the bacteriophage. In some embodiments, the activity of the CRISPR-Cas system complements or enhances the lytic activity of the bacteriophage. In some embodiments, the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system are synergistic. In some embodiments, the lytic activity of the bacteriophage, the activity of the CRISPR-Cas system, or both, is regulated by the concentration of the bacteriophage. In some embodiments, the bacteriophage infects multiple bacterial strains. In some embodiments, the bacteriophage is an obligately lytic bacteriophage. In some embodiments, the bacteriophage is a lysogenic bacteriophage that has been rendered lytic. In some embodiments, temperate bacteriophages are rendered lytic by removal, replacement, or inactivation of lysogenic genes.In some embodiments, the bacteriophage is one of PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimatre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the bacteriophage used herein includes any one or more of p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the bacteriophage is a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a bacteriophage selected from p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, and PB1.In some embodiments, the bacteriophages used herein include p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p 2131wt, p2132e002, p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or two or more phages thereof. In some embodiments, the bacteriophage used herein is selected from the group consisting of p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p2131wt, p2132e002, p2132wt, p2167wt, p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or any one or more of bacteriophages having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to two or more phages thereof. In some embodiments, the bacteriophage used herein is selected from the group consisting of p1106e003, p1835e002, p2131e002, p1772e005, p1194, and p1695. In some embodiments, the bacteriophage in the bacteriophage cocktail system used herein includes any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695. In some embodiments, the nucleic acid sequence is inserted into a non-essential bacteriophage.Disclosed herein in some embodiments is a pharmaceutical composition comprising (a) a bacteriophage disclosed herein and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises at least two different bacteriophages. In some embodiments, the pharmaceutical composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 different bacteriophages. In some embodiments, the pharmaceutical composition comprises at least six different bacteriophages. In some embodiments, the pharmaceutical composition comprises at least six different bacteriophages, and bacteriophages as used herein include any one or more of p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the pharmaceutical composition comprises at least six different bacteriophages, and bacteriophages as used herein include p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695. In some embodiments, the pharmaceutical composition is in the form of a tablet, capsule, liquid, syrup, oral formulation, intravenous formulation, intranasal formulation, ophthalmic formulation, otic formulation, subcutaneous formulation, topical formulation, transdermal formulation, transmucosal formulation, inhalable respiratory formulation, suppository, lyophilized formulation, nebulizable formulation, and any combination thereof. In some embodiments, the pharmaceutical composition comprises p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695 in a nebulizable formulation for pulmonary delivery.
[0010]
[0009] In certain aspects herein, disclosed are methods of cleaning a surface in need of cleaning, comprising administering to the surface a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system, the type I CRISPR-Cas system comprising a CRISPR array, a Cascade polypeptide comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, and a Cas3 polypeptide. In some embodiments, the surface is a hospital surface, a vehicle surface, an equipment surface, or an industrial surface.
[0011]
[0009] In certain aspects herein, a method of preventing contamination of a food product or dietary supplement is disclosed, comprising contacting the food product or dietary supplement with a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system, the type I CRISPR-Cas system comprising a CRISPR array, a Cascade polypeptide comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, and a Cas3 polypeptide. In some embodiments, the food product or dietary supplement comprises milk, yogurt, curd, cheese, fermented milk, fermented milk products, ice cream, fermented grain products, milk powders, infant formula or tablets, liquid suspensions, dry oral supplements, wet oral supplements, or dry-tube-feeding.
[0012] In certain aspects, disclosed herein is a bacteriophage comprising a nucleic acid sequence encoding a Type I CRISPR-Cas system comprising a CRISPR array, a Cascade polypeptide, and a Cas3 polypeptide, wherein the CRISPR array comprises a spacer sequence complementary to a target nucleotide sequence in Pseudomonas species, wherein the spacer sequence comprises SEQ ID NOs: 12, 16, and 20.
[0013] In certain embodiments disclosed herein are bacteriophages that comprise at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a phage selected from p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the bacteriophages used herein include p1106e003, p1106wt, p1194wt, p1587e002, p1587wt, p1695wt, p1772e005, p1772wt, p1835e002, p1835wt, p2037e002, p2037wt, p2131e002, p2131wt, p2132e002, p2132wt, p2167wt , p2363e003, p2363wt, p2421e002, p2421wt, p2973e002, p2973wt, p3278wt, p4430wt, PB1e002, or PB1wt, or a bacteriophage having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to two or more of these phages. In some embodiments, a bacteriophage cocktail system comprising two or more bacteriophages is provided. In some embodiments, the bacteriophage cocktail system comprises bacteriophage of CK000512 (p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695). In some embodiments, the bacteriophage further comprises a CRISPR array, a Cascade polypeptide comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array further comprises at least one repeat sequence.In some embodiments, at least one repeat sequence is operably linked at either its 5' or 3' end to one or more spacer sequences. In some embodiments, the repeat sequence comprises at least about 90% sequence identity to any one of SEQ ID NOS: 26-30. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOS: 83-87. In some embodiments, the target nucleotide sequence comprises a coding sequence. In some embodiments, the target nucleotide sequence comprises a non-coding or intergenic sequence. In some embodiments, the target nucleotide sequence comprises all or a portion of a promoter sequence. In some embodiments, the promoter sequence comprises at least about 90% sequence identity to any one of SEQ ID NOS: 1-11.
[0014] Disclosed herein in certain aspects are compositions comprising at least four bacteriophages, the compositions comprising: a first bacteriophage comprising or having at least 80% sequence identity to p1106e003; a second bacteriophage comprising or having at least 80% sequence identity to p1835e002; a third bacteriophage comprising or having at least 80% sequence identity to p1772e005; and a fourth bacteriophage comprising or having at least 80% sequence identity to p2131e002. In some embodiments, the compositions further comprise a fifth bacteriophage comprising or having at least 80% sequence identity to p1194. In some embodiments, the composition further comprises a fifth bacteriophage that comprises p1695 or has at least 80% sequence identity to p1695. In some embodiments, the composition further comprises a fifth bacteriophage that comprises p4430 or has at least 80% sequence identity to p4430. In some embodiments, the composition further comprises a sixth bacteriophage that comprises p1695 or has at least 80% sequence identity to p1695. In some embodiments, the composition comprises bacteriophages of CK000512 (p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695).
[0015] In any of the embodiments of the methods herein, the bacteriophage of the method is engineered from a bacteriophage that infects Pseudomonas. In some embodiments, the bacteriophage that infects Pseudomonas includes a subtype of wild-type Pbuna virus phage listed in Table 5A, which infects the target Pseudomonas as marked with a plus sign (+) (e.g., phage p1106 infects b002548). In some embodiments, the bacteriophage that infects Pseudomonas includes an engineered subtype of Pbuna virus phage listed in Table 5A, which infects the target Pseudomonas as marked with a plus sign (+) (e.g., p1106e003 infects b002548). In some embodiments, the bacteriophage that infects the Pseudomonas includes a wild-type Samuna virus phage subtype, an engineered Samuna virus phage subtype, a wild-type PhiKZ virus, a wild-type PhiKMV virus, or a wild-type Bruynoghe virus, e.g., as listed in Table 5B, which infects the target Pseudomonas as marked with a plus sign (+). As listed in Table 5A, the wild-type Pbuna virus phage subtype can be p1106, p1587, p1835, p2037, p2363, p2421, and / or pb1, while the engineered Pbuna virus phage subtype can be p1106e003, p1587e002, p1835e002, p2037e002, p2363e003, and / or p2421e002.As listed in Table 5B, the phage subtype of wild-type Samuna virus can be p1772, p2131, p2132, and / or p2973; the phage subtype of engineered Samuna virus can be pb1e002, p1772e005, p2131e002, p2132e002, and / or p2973e002; the phage subtype of wild-type PhiKZ virus can be p1194 and / or p4430; the phage subtype of wild-type PhiKMV virus can be p2167; and the phage subtype of wild-type Bruynoghe virus can be p1695 and / or p3278. In some embodiments, the bacteriophage that infects Pseudomonas is Nankoku virus, PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimtre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the bacteriophage that infects Pseudomonas kills Pseudomonas. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Staphylococcus aureus. In some embodiments, bacteriophages that infect Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that infect Pseudomonas do not infect Klebsiella pneumoniae.In some embodiments, the bacteriophage that infects Pseudomonas does not kill Klebsiella pneumoniae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Klebsiella pneumoniae. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Klebsiella pneumoniae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterococcus faecium. In some embodiments, bacteriophage that infect Pseudomonas do not infect Enterobacter cloacae. In some embodiments, bacteriophage that infect Pseudomonas do not kill Enterobacter cloacae. In some embodiments, bacteriophage that infect Pseudomonas do not infect Enterobacter cloacae. In some embodiments, bacteriophage that infect Pseudomonas do not infect Enterobacter cloacae. In some embodiments, bacteriophage that kill Pseudomonas do not kill Enterobacter cloacae. In some embodiments, bacteriophage that infect Pseudomonas do not infect Acinetobacter baumannii. In some embodiments, bacteriophage that infect Pseudomonas do not kill Acinetobacter baumannii. In some embodiments, bacteriophage that infect Pseudomonas do not infect Acinetobacter baumannii. In some embodiments, a bacteriophage that kills Pseudomonas does not kill Acinetobacter baumannii. In some embodiments, a bacteriophage that infects Pseudomonas does not infect Staphylococcus epidermidis. In some embodiments, a bacteriophage that infects Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, a bacteriophage that kills Pseudomonas does not infect Staphylococcus epidermidis.In some embodiments, the bacteriophage that kills Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the combination of bacteriophages infects Pseudomonas. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B. In some embodiments, the bacteriophage combination kills Pseudomonas. By way of non-limiting example, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B. [Brief explanation of the drawings]
[0016] The novel features of the present disclosure are set forth with particularity in the appended claims. The features and advantages of the present disclosure will be better understood by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings.
[0017] [Figure 1A] FIG. 1 shows the sequence and organization of crArray1 (SEQ ID NO: 83). [Figure 1B] FIG. 1 shows the sequence and organization of crArray2 (SEQ ID NO: 84). [Figure 1C] FIG. 1 shows the sequence and organization of crArray3 (SEQ ID NO: 85). [Figure 1D] FIG. 1 shows the sequence and organization of crArray4 (SEQ ID NO: 86). [Figure 1E] FIG. 1 depicts the sequence and organization of crArray5 (SEQ ID NO: 87). [Figure 1F] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1G] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1H] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1I] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1J] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1K] FIG. 1 depicts the arrangement of crArray1 and PaIC insert (SEQ ID NO: 25). [Figure 1L] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 1M] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 1N] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 1O] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 1P] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 1Q] FIG. 1 depicts the arrangement of crArray3 and PaIC insert (SEQ ID NO: 24). [Figure 2A] (Upper panel) The effect of transforming two P. aeruginosa strains with a plasmid containing crRNA using the endogenous CRISPR-Cas3 system, as measured by the number of transformants in colony-forming units (CFU). The lower panel shows the effect of transforming P. aeruginosa with a plasmid containing both a three-spacer crRNA and an exogenous IC-type Cas operon, resulting in fewer transformants than the limit of detection. [Figure 2B] Figure 1 shows the number of bacterial transformants obtained per mL of transformation into a Cas operon null mutant of Pseudomonas aeruginosa strain b1121. Array 1 targets the bacterial genome, and array 2 is a non-targeting control. The various plasmids were normalized by molar concentration to the empty vector control plasmid. [Figure 2C] FIG. 1 shows the effect of transforming individual spacers targeting rpoB, ftsA, or the 3-spacer arrays Array 3 or Array 4 into P. aeruginosa strains with (b1121) or without the endogenous type IC Cas operon (b1121 cas KO). [Figure 3A]
[0023] Figure 1 depicts a schematic of the genomes of wild-type phage p1772 and its engineered mutants. Bars below the genome axes indicate the regions of the genome that were removed and replaced. The diagram below the phage genome illustrates the DNA used to replace the WT phage genes in the deleted regions. Arrays 1, 3, and 4 target the bacterial genome and kill bacteria in the presence of an IC-type Cas operon. Array 2's spacer is untargeted, but the array is structurally identical to the three targeting arrays. [Figure 3B] Figure 1 compares the sequences of p1772e005 (targeted crArray1+Cas system) after 5 or 10 passages at 37° C. No differences were observed at the nucleotide level in the insert, indicating the stability of the engineered phage expressing CRISPR-Cas3. [Figure 4] Figure 1 illustrates that CRISPR-Cas3 engineered phage do not exhibit structural changes. When imaged by TEM, no gross morphological differences were observed between p1772wt (wild type), p1772e004 (Cas system only), and p1772e005 (targeted crArray+Cas system). [Figure 5A] Figure 5 illustrates complete phage constructs that amplify similarly to the wild-type parent phage and retain similar host ranges in various Cas-type mutants. Figure 5A shows the in vitro amplification titers of p1772wt (wild-type), p1772e004 (Cas system), and p1772e005 (targeted crArray1+Cas system) against P. aeruginosa strains containing IF-type Cas systems. A phage is considered to infect a given strain if the AUC in the presence of phage / AUC in the absence of phage is less than 0.65. [Figure 5B]Figure 5B illustrates the complete phage constructs that amplify similarly to the wild-type parent phage and retain similar host ranges in various Cas-type mutants. Figure 5B shows the in vitro amplification titers of p1772wt and p1772e005 against P. aeruginosa strains containing the IC-type Cas system. A phage is considered to infect a given strain if the AUC in the presence of phage / AUC in the absence of phage is less than 0.65. [Figure 5C] Figure 5A illustrates the complete phage constructs that amplify similarly to the wild-type parent phage and retain similar host ranges in various Cas-type mutants. Figure 5C shows the host ranges of p1772wt, p1772e004, and p1772e005 on 44 strains of P. aeruginosa. A phage is considered to infect a given strain if the AUC in the presence of phage / AUC in the absence of phage is less than 0.65. [Figure 6A] Figure 6 illustrates that an exogenous CRISPR-Cas3 system is efficiently expressed from the phage genome. Figure 6A shows a diagram of the spacer array and Cas operon inserted into engineered variants of p1772. [Figure 6B] Figure 6B-6D demonstrate that the exogenous CRISPR-Cas3 system is efficiently expressed from the phage genome. Figures 6B-6D show the expression of crArray, Cas3, and Cas8 in P. aeruginosa strain b1121 infected with p1772wt (wild type) or p1772e005 (targeted crArray1+Cas system) over a 1600 minute period. [Figure 6C] Figure 6B-6D demonstrate that the exogenous CRISPR-Cas3 system is efficiently expressed from the phage genome. Figures 6B-6D show the expression of crArray, Cas3, and Cas8 in P. aeruginosa strain b1121 infected with p1772wt (wild type) or p1772e005 (targeted crArray1+Cas system) over a 1600 minute period. [Figure 6D]Figure 6B-6D demonstrate that the exogenous CRISPR-Cas3 system is efficiently expressed from the phage genome. Figures 6B-6D show the expression of crArray, Cas3, and Cas8 in P. aeruginosa strain b1121 infected with p1772wt (wild type) or p1772e005 (targeted crArray1+Cas system) over a 1600 minute period. [Figure 6E]
[0033] Figure 6E illustrates that exogenous CRISPR-Cas3 systems are efficiently expressed from the phage genome. Figure 6E shows Cas3 expression at 1 and 24 hours post-infection with p1772e005, p2131e002 (targeted crArray1+Cas system), and p2132e002 (targeted crArray1+Cas system). [Figure 7] FIG. 1 shows plaques formed by plating p1772wt (wild type) or p1772e005 (targeted crArray1+Cas system) onto P. aeruginosa. [Figure 8A] Figure 1 illustrates the results of a plate-based killing assay. p1772wt (wild type), p1772e004 (Cas system only), p1772e006 (targeted crArray1 only), and p1772e005 (targeted crArray1 + Cas system) were mixed with P. aeruginosa at multiplicities of infection (MOI) ranging from 100 to 0.0000954. [Figure 8B] FIG. 8B depicts a higher magnification section of the plate set out in FIG. 8A. [Figure 8C] Figure 1 shows quantification of relative fluorescence units of P. aeruginosa infected with p1772wt, p1772e008 (non-targeting crArray2+Cas system), p1772e006, and p1772e005 at an MOI of 1.5. [Figure 9A] FIG. 10 depicts the growth of p1772wt (wild type), p1772e004 (Cas system only), p1772e005 (targeted crArray1 + Cas system), and p1772e006 (targeted crArray1 only) in P. aeruginosa strain b1121 over 24 hours when inoculated at an MOI of 1. [Figure 9B]FIG. 10 depicts the growth of p1772wt, p1772e004, p1772e005, and p1772e006 in P. aeruginosa strain b1121 over 24 hours when inoculated at an MOI of 10. [Figure 9C] FIG. 10 depicts the growth of p1772wt, p1772e004, p1772e005, and p1772e006 in P. aeruginosa strain b1121 over 24 hours when inoculated at an MOI of 100. [Figure 10A] Figure 11 depicts the growth on agar plates of P. aeruginosa cultures mixed with p1772wt (wild type), p1772e008 (non-targeted crArray2 + Cas system), p1772e006 (targeted crArray1 only), and pArray3 (targeted crArray3 + Cas system) at MOIs of 100 to 0.0001. [Figure 10B] FIG. 10 depicts the growth on agar plates of P. aeruginosa cultures mixed with p1772wt, p1772e008, p1772e006, and pArray4 (targeted crArray4+Cas system) at MOIs of 100 to 0.0001. [Figure 10C] Diagram of insert from Figure 10A, showing fold-in of p1772e006 compared to pArray3 at MOIs of 0.0244 (top row) and 0.00610 (bottom row). [Figure 10D] FIG. 10A shows quantification of the fluorescent signal from bacteria after infection with phage at an MOI of about 1.5. [Figure 10E] Quantification of the fluorescent signal from bacteria after infection with phage at an MOI of about 1.5 in FIG. 10B. [Figure 11A] Figure 11A depicts the growth on agar plates of P. aeruginosa cultures mixed with p1772 mutants bearing different promoters. Figure 11A shows the growth on agar plates of P. aeruginosa cultures mixed with p1772wt (wild-type) and mutants containing the same crArray 1 and Cas system, where the Cas system was driven by different promoters at an MOI of 100 to 0.00001. [Figure 11B]Figure 11B shows the growth on agar plates of P. aeruginosa cultures mixed with p1772 mutants bearing different promoters. Figure 11B shows the quantification of fluorescence of the cells at an MOI of 1.5 in Figure 11A. [Figure 12A] FIG. 10 depicts quantification of fluorescence from growth on agar plates of P. aeruginosa cultures mixed with p2132wt (wild type) and p2132e002 (targeted crArray1+Cas system) at an MOI of 1.5. [Figure 12B] FIG. 10 depicts quantification of fluorescence from growth on agar plates of P. aeruginosa cultures mixed with p2973wt (wild type) and p2973e002 (targeted crArray1+Cas system) at an MOI of 1.5. [Figure 13] Growth on agar plates of various strains of P. aeruginosa cultures mixed with various phage mutants. p4209wt (wild-type) and p4209e002 (targeted crArray1+Cas system) were mixed with P. aeruginosa strains b2550 (IE-type Cas), b2631 (IF-type Cas), b2816 (IE / IF-type Cas), and b2825 (inactive type I Cas) and plated after 0, 3, or 24 hours of incubation. [Figure 14] Figure 1 shows the efficacy of crArray / Cas inserts against multiple P. aeruginosa strains. p4209wt (wild-type), p4209e001 (Cas system only), and p4209e002 (targeted crArray1+Cas system) formed plaques on P. aeruginosa strains b2550 (IE-type Cas), b2631 (IF-type Cas), b2816 (IE / IF-type Cas), and b2825 (inactive type I Cas). [Figure 15A] Figure 15 illustrates the in vivo efficacy of p1772wt (wild type) compared to p1772e005 (targeted crArray1+Cas system). Figure 15A is a diagram representing the experimental setup in Figures 15B-15D. [Figure 15B]Figure 15B illustrates in vivo efficacy comparing p1772wt (wild type) and p1772e005 (targeted crArray1+Cas system). Figure 15B shows phage efficacy when injected into mouse thigh muscle. The left panel shows the number of colony-forming units (CFU) recovered 6 hours post-infection. The right panel shows the number of plaque-forming units (PFU) recovered 6 hours post-infection. [Figure 15C] Figure 15C illustrates in vivo efficacy comparing p1772wt (wild type) with p1772e005 (targeted crArray1+Cas system). Figure 15C depicts phage efficacy when injected into mouse thigh muscle, along with the number of CFU (top) and PFU (bottom) recovered at 8 and 24 hours post-infection. [Figure 15D] Figure 15D illustrates the in vivo efficacy of p1772wt (wild type) compared to p1772e005 (targeted crArray1+Cas system). Figure 15D depicts the efficacy of phage when administered intravenously, along with the number of CFU (top) and PFU (bottom) recovered at 9, 12, 15, and 24 hours post-infection. [Figure 15E] FIG. 15B is a diagram showing the experimental setup for FIG. 15F. [Figure 15F] Dose response to treatment with p1772wt and p1772e005, showing the amount of CFU (top) and PFU (bottom) recovered at 8 and 24 hours post-infection. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA with multiple comparisons or two-way ANOVA with Tukey's test. [Figure 16] FIG. 1 illustrates a CRISPR-Cas3 engineered reference phage in which PB1e002 (crArray1+Cas system) acts in concert with p1772e005 (crArray1+Cas system). [Figure 17] FIG. 1 depicts the number of transformants produced after transfecting Pseudomonas with inserts containing various spacer sequences. [Figure 18A] FIG. 1 depicts the assay used to test the efficiency of CRISPR-engineered phages alone or in cocktails. [Figure 18B] FIG. 1 shows the effect of cocktail treatment on mice infected with P. aeruginosa b2631. [Figure 18C] FIG. 1 shows the effect of cocktail treatment on mice infected with P. aeruginosa b1121. [Figure 18D] FIG. 1 shows the effect of cocktail treatment on mice infected with P. aeruginosa b3144. [Figure 18E] FIG. 1 depicts the effect of treatment with CRISPR-engineered phage compared to wild-type phage. [Figure 18F] FIG. 1 depicts a graphical representation of the assay used to test the effectiveness of the cocktail compared to treatment with individual phages. [Figure 18G] FIG. 1 shows the effect of treatment with individual phages or phage cocktails (as indicated) on mice infected with P. aeruginosa b2631. [Figure 18H] FIG. 1 shows the effect of treatment with cocktail or individual phages on mice infected with P. aeruginosa b3144. [Figure 18I] FIG. 1 shows the effect of treatment with cocktails or individual phages on mice infected with P. aeruginosa. [Figure 19A] FIG. 1 depicts the assay used to test the effectiveness of the cocktail. [Figure 19B] FIG. 1 shows the effect of treatment with phage cocktail CK125 on mice infected with P. aeruginosa b2631. [Figure 19C] FIG. 1 shows the effect of cocktail treatment on mice infected with P. aeruginosa b1121. [Figure 19D] Figure 1 shows the effect of cocktail treatment on mice infected with P. aeruginosa b3144. TOB = tobramycin. [Figure 20A]FIG. 1 shows a graphical representation of the experimental setup for testing the anti-biofilm activity of phage cocktail CK125 against pre-formed biofilms from primary Pseudomonas aeruginosa strains b1121 and b2631 using the minimum biofilm-eradicating concentration (MBEC) assay. [Figure 20B] The left side shows % inhibition at 24 hours, the middle shows % inhibition at 48 hours. The table on the right shows comparative data showing MBEC IC50 with the phage cocktail or ciprofloxacin. [Figure 21] (Upper panel) Experimental setup and results for testing the antibiofilm activity of phage cocktail PACK512 against biofilms from respiratory / clinical isolates of Pseudomonas aeruginosa strains b1121, b2631, and b2631 using the minimum biofilm eradicating concentration (MBEC) method. Figure 22 (lower panel) shows the % inhibition at 24 h on the left and % inhibition at 48 h on the right. [Figure 22A] FIG. 1 shows the assay setup for testing the bactericidal activity of the cocktail in the presence of human mucin. [Figure 22B] Assay results showing bacterial load for various treatments: on the left, results for inhibition of P. aeruginosa strain b1121 from respiratory isolates; on the right, results for inhibition of P. aeruginosa strain b2631 from CF isolates. [Figure 23A] FIG. 1 shows the assay set-up for testing the bactericidal effect of the cocktail in the presence of mucin and a comparison with tobramycin. [Figure 23B] FIG. 1 shows the bacterial load in the presence of the cocktail or tobramycin treatment compared to the no treatment control. [Figure 24] FIG. 1 shows data from phage level testing after eradication in a Pseudomonas aeruginosa lower respiratory tract infection model. DETAILED DESCRIPTION OF THE INVENTION
[0018] Disclosed herein in certain embodiments is a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system comprising (a) a CRISPR array (also referred to as "crArray"), (b) a Cascade polypeptide, and (c) a Cas3 polypeptide. Disclosed herein in certain embodiments is a pharmaceutical composition comprising the bacteriophage disclosed herein. Also disclosed herein in certain embodiments is a method of killing Pseudomonas species, comprising introducing into the Pseudomonas species a bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system, wherein the type I CRISPR-Cas system comprises (a) a CRISPR array, (b) a Cascade polypeptide, and (c) a Cas3 polypeptide. Further disclosed in certain embodiments herein is a method of treating a disease or condition in an individual in need thereof, the method comprising administering to the individual a bacteriophage comprising a nucleic acid sequence encoding a Type I CRISPR-Cas system, the Type I CRISPR-Cas system comprising (a) a CRISPR array, (b) a Cascade polypeptide, and (c) a Cas3 polypeptide.
[0019] Specific Terms Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used to describe the disclosure herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.
[0020] Unless the context dictates otherwise, it is specifically intended that the various features of the present disclosure described herein can be used in any combination.Furthermore, the present disclosure also contemplates that in some embodiments, any feature or combination thereof specified herein may be excluded or omitted.For illustrative purposes, when a composition is described herein as comprising components A, B, and C, it is specifically intended that any of A, B, or C, or any combination thereof, alone or in any combination, may be omitted and excluded.
[0021] Those skilled in the art will appreciate the interchangeability of such terms due to a lack of consistency in the literature and ongoing efforts in the art to unify the terminology designating various CRISPR-Cas systems and their components.
[0022] As used in this specification and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Also, as used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").
[0023] The term "about," as used herein, when referring to a measurable value such as dosage or duration, refers to a variation of ±20%, ±10%, ±5%, ±1%, +0.5%, or even ±0.1% of the specified amount. As used herein, phrases such as "between X and Y" or "between about X and Y" should be interpreted to include X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y," and phrases such as "between about X and Y" mean "between about X and about Y."
[0024] The terms "comprise," "comprises," and "comprising," "includes," "including," "have," and "having," as used herein, specify the presence of stated features, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, steps, operations, elements, and / or components.
[0025] As used herein, the transitional phrase "consisting essentially of" means that the scope of a claim should be construed to include the specific materials or steps recited in the claim without materially affecting the basic and novel characteristics of the claimed disclosure. Thus, the term "consisting essentially of" is not intended to be construed as equivalent to "comprising" when used in the claims of this disclosure.
[0026] The terms "consists of" and "consisting of," when used herein, exclude all features, steps, operations, elements, and / or components not specifically and directly recited. The use of "consisting of" is limited to only the features, steps, operations, elements, and / or components that are described in that clause; other features, steps, operations, elements, and / or components are excluded from the claim as a whole.
[0027] The terms "complementary" or "complementarity," as used herein, refer to the natural binding of polynucleotides by base pairing under permissive salt and temperature conditions. For example, the sequence "AGT" binds to the complementary sequence "TCA." Complementarity between two single-stranded molecules can be "partial," where only a portion of the nucleotides are bound, or complete, where all complementarity exists between the single-stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands.
[0028] "Complement," as used herein, means 100% complementarity or identity to a reference nucleotide sequence, or less than 100% complementarity (e.g., about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, etc. complementarity). Complement or complementable may also be used in reference to the "complement" of a mutation or "complementing" a mutation.
[0029] As used herein, the terms "CRISPR phage," "CRISPR-enhanced phage," and "crPhage" refer to a bacteriophage particle (e.g., a CRISPR array, a crRNA, e.g., a P1 bacteriophage containing a targeting crRNA insert) that contains bacteriophage DNA containing at least one heterologous polynucleotide encoding at least one component of a CRISPR-Cas system. In some embodiments, the polynucleotide encodes at least one transcriptional activator of the CRISPR-Cas system. In some embodiments, the polynucleotide encodes at least one component of an anti-CRISPR polypeptide of the CRISPR-Cas system.
[0030] As used herein, the phrase "substantially identical" or "substantial identity" in the context of two nucleic acid molecules, nucleotide sequences, or protein sequences, when compared and aligned for maximum correspondence, means a sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1110%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, Substantial identity refers to 1%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and / or 100% nucleotide or amino acid residue identity. In some embodiments, substantial identity refers to two or more sequences or subsequences having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95, 96, 96, 97, 98, or 99% identity. In sequence comparison, generally, one sequence serves as a reference sequence to which test sequences are compared.When using sequence comparison algorithm, test sequences and reference sequences are input into a computer, and if necessary, the coordinates of subsequences are designated, and subsequence algorithm program parameters are designated.Then, the sequence comparison algorithm calculates the percent sequence identity of the test sequence to the reference sequence based on the designated program parameters.
[0031] Optimal sequence alignment for aligning a comparison window is performed by tools such as the Smith and Waterman local homology algorithm, the Needleman and Wunsch homology alignment algorithm, the Pearson and Lipman similarity search method, and optionally by computer implementations of the above algorithms, such as GAP, BESTFIT, FASTA, and TFASTA, available as part of the GCG® Wisconsin Package® (Accelrys Inc., San Diego, CA). The "identity fraction" for aligned segments of a test sequence and a reference sequence is the number of identical components shared by the two aligned sequences divided by the total number of components in the reference sequence segment, i.e., the entire reference sequence or a defined small portion of the reference sequence. The percentage of sequence identity is expressed by multiplying the identity fraction by 100. Comparison of one or more polynucleotide sequences can be performed on full-length polynucleotide sequences or portions thereof, or on longer polynucleotide sequences. In some instances, "percent identity" is determined using BLASTX version 2.0 for translated nucleotide sequences and BLASTN version 2.0 for polynucleotide sequences.
[0032] As used herein, a "target nucleotide sequence" refers to a portion of a target gene (i.e., a target region in the genome adjacent to a protospacer adjacent motif (PAM) sequence or "protospacer sequence") that is fully complementary or substantially complementary (e.g., at least 70% complementary (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)) to a spacer sequence in a CRISPR array.
[0033] As used herein, the term "protospacer adjacent motif" or "PAM" refers to a DNA base sequence present on a target DNA molecule adjacent to a nucleotide sequence matching the spacer sequence. This motif is found in the target gene adjacent to the region to which the spacer sequence binds by being complementary to the region, and identifies the point at which base pairing with the spacer nucleotide sequence begins. The exact PAM sequence required varies between different CRISPR-Cas systems. Non-limiting examples of PAMs include CCA, CCT, CCG, TTC, AAG, AGG, ATG, GAG, and / or CC. In some examples, in Type I systems, the PAM is located immediately 5' to the sequence matching the spacer, so it is 3' to the sequence that base pairs with the spacer nucleotide sequence and is directly recognized by the Cascade. In some examples, in Type IC systems of B. halodurans, the PAM is YYC, where Y can be either T or C. In some examples, in Type IC systems of Pseudomonas aeruginosa, the PAM is TTC. Once the cognate protospacer and PAM are recognized, Cas3 is recruited, subsequently cleaving and degrading the target DNA. In Type II systems, the PAM is required for Cas9 / sgRNA to form an R-loop to interrogate specific DNA sequences via Watson-Crick pairing of its guide RNA with the genome. The specificity of the PAM depends on the DNA binding specificity of the Cas9 protein (e.g., the protospacer adjacent to the motif recognition domain at the C-terminus of Cas9).
[0034] As used herein, the term "gene" refers to a nucleic acid molecule that can be used to produce mRNA, tRNA, rRNA, miRNA, anti-microRNA, regulatory RNA, etc. A gene may or may not be usable to produce a functional protein or gene product. A gene includes both coding and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences, and / or 5' and 3' untranslated regions). A gene is "isolated" in the sense that the nucleic acid is substantially or essentially free from components that are normally found associated with the nucleic acid in its natural state. Such components include other cellular material, culture medium from recombinant production, and / or various chemicals used in the chemical synthesis of the nucleic acid.
[0035] The terms "treat," "treating," or "treatment" are intended to mean that the severity of the disease in a subject is reduced or at least partially ameliorated, and that some alleviation, relief, or reduction in at least one clinical symptom is achieved, and / or a delay in the progression of the disease or condition and / or a delay in the onset of the disease or condition is observed. With respect to an infection, disease, or condition, the term refers to a reduction in the symptoms or other signs of the infection, disease, or condition. In some embodiments, treatment reduces the symptoms or other signs of the infection, disease, or condition by at least about 5%, e.g., about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more.
[0036] The terms "prevent," "preventing," and "prevention" (and grammatical variations thereof) refer to preventing and / or delaying the onset of, and / or reducing the severity of, an infection, disease, illness, and / or clinical symptom in a subject compared to what would occur if the methods of the present disclosure were not performed prior to the onset of the infection, disease, illness, and / or clinical symptom. Thus, in some embodiments, foods, surfaces, medical tools, and devices are treated with the compositions and methods disclosed herein to prevent infection.
[0037] As used herein, the terms "infection," "disease," or "illness" refer to any adverse, negative, or harmful physiological condition in a subject that is caused by the presence of a target bacterium in the subject. These terms are used interchangeably.
[0038] The terms "individual" or "subject," as used herein, include any animal that has or is susceptible to a bacterium involved in an infection, disease, or illness. Thus, in some embodiments, the subject is a mammal, bird, reptile, amphibian, fish, crustacean, or mollusk. Mammalian subjects include, but are not limited to, humans, non-human primates (e.g., gorillas, monkeys, baboons, chimpanzees, etc.), dogs, cats, goats, horses, pigs, cows, sheep, etc., and laboratory animals (e.g., rats, guinea pigs, mice, gerbils, hamsters, etc.). Avian subjects include, but are not limited to, chickens, ducks, turkeys, geese, quail, pheasants, and pet birds (e.g., parakeets, parrots, macaws, lovebirds, canaries, etc.). Piscenic subjects include, but are not limited to, species used in aquaculture (e.g., tuna, salmon, tilapia, catfish, carp, trout, cod, bass, sea bass, snapper, etc.). Crustacean subjects include, but are not limited to, species used in aquaculture (e.g., shrimp, prawns, lobsters, crayfish, crabs, etc.). Molluscic subjects include, but are not limited to, species used in aquaculture (e.g., abalone, mussels, oysters, clams, scallops, etc.). In some embodiments, suitable subjects include both male and female subjects of all ages, including fetuses (e.g., in utero or in ovo), infants, young children, adolescents, adults, and geriatric subjects. In some embodiments, the subject is a human.
[0039] As used herein, the term "isolated" in the context of a nucleic acid sequence is a nucleic acid sequence that exists apart from its natural environment.
[0040] As used herein, "expression cassette" means a recombinant nucleic acid molecule (e.g., the recombinant nucleic acid molecules and CRISPR arrays disclosed herein) comprising a nucleotide sequence of interest, wherein the nucleotide sequence is operably linked to at least one control sequence (e.g., a promoter).
[0041] As used herein, "chimera" refers to a nucleic acid molecule or polypeptide in which at least two components are derived from different sources (eg, different organisms, different coding regions).
[0042] As used herein, "selectable marker" means a nucleotide sequence which, when expressed, confers a distinct phenotype on a host cell expressing the marker, thereby allowing cells so transformed to be distinguished from cells that do not carry the marker.
[0043] As used herein, a "vector" refers to a composition for transcribing, delivering, or introducing a nucleic acid (or nucleic acids) into a cell.
[0044] As used herein, "pharmaceutically acceptable" means a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject without producing any undesirable biological effects, such as toxicity.
[0045] As used herein, the term "biofilm" refers to an accumulation of microorganisms embedded in a polysaccharide matrix. Biofilms occur on solid biological or non-biological surfaces and are medically important, accounting for more than 80 percent of microbial infections in the body.
[0046] As used herein, the term "in vivo" is used to describe events that occur in the body of a subject.
[0047] As used herein, the term "in vitro" is used to describe an event in which the material is contained in a container to hold a test reagent, such that the material is separated from the biological source from which it is obtained. In vitro assays can include cell-based assays that utilize living or dead cells. In vitro assays can also include cell-free assays that do not utilize intact cells.
[0048] CRISPR / CAS system The CRISPR-Cas system is a natural adaptive immune system found in bacteria and archaea. The CRISPR system is a nuclease system involved in defense against phage and plasmid invasion, providing a form of adaptive immunity. Based on the set of cas genes and their phylogenetic relationships, there are a variety of CRISPR-Cas systems. There are at least six different types (I-VI), with Type I representing more than 50% of all systems identified in both bacteria and archaea. In some embodiments, Type I, Type II, Type III, Type IV, Type V, or Type VI CRISPR-Cas systems are used herein.
[0049] Type I systems are divided into seven subtypes, including types IA, IB, IC, ID, IE, IF, and IU. Type I CRISPR-Cas systems comprise a multisubunit complex called Cascade (in the complex involved in antiviral defense), Cas3 (a protein with nuclease, helicase, and exonuclease activities that contributes to target DNA degradation), and a CRISPR array encoding crRNA (which stabilizes the Cascade complex and directs Cascade and Cas3 to the DNA target). Cascade forms a complex with crRNA, and the protein-RNA pair recognizes its genomic target through complementary base pairing between the 5' end of the crRNA sequence and a predefined protospacer. This complex is directed to homologous loci in pathogen DNA via reagents encoded within the crRNA and protospacer adjacent motifs (PAMs) in the pathogen genome. Base pairing occurs between the crRNA and the target DNA sequence, triggering a conformational transition. In the IE system, the PAM is recognized by the CasA protein within the Cascade, which subsequently releases it from the adjacent DNA and evaluates the degree of base pairing between the target and spacer portions of the crRNA. Upon sufficient recognition, the Cascade is recruited to activate Cas3, which then nicks the non-target strand and begins to degrade the strand in the 3' to 5' direction.
[0050] In IC-type systems, the proteins Cas5, Cas8c, and Cas7 form a cascade effector complex. Cas5 processes pre-crRNA (which can be in the form of a multiple spacer array or a single spacer between two repeats) to produce individual crRNAs that are calibrated with a hairpin structure formed from the remaining repeat and linear sequences. The effector complex then binds to the processed crRNA and scans the DNA to identify a PAM site. In IC-type systems, the PAM is recognized by the Cas8c protein, which then acts to release the DNA duplex. If the sequence 3' of the PAM matches the crRNA spacer bound by the effector complex, a conformational change occurs in the complex, recruiting Cas3 to the site. Cas3 then nicks the non-target strand and begins DNA degradation. In some cases, Cas5 contains a sequence at least 90% identical to Cas5, Cas5c, Cas5d, and SEQ ID NO: 76. Optionally, the Cas7 comprises a sequence at least 90% identical to Cas7, Cas7c, and SEQ ID NO: 78. Optionally, the Cas8 comprises a sequence at least 90% identical to Cas8, Cas8c, and SEQ ID NO: 77.
[0051] In some embodiments, the CRISPR-Cas system is endogenous to the Pseudomonas species. In some embodiments, the CRISPR-Cas system is exogenous to the Pseudomonas species. In some embodiments, the CRISPR-Cas system is a type I CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IA CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IB CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IC CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IC CRISPR-Cas system from Pseudomonas aeruginosa. In some embodiments, the CRISPR-Cas system is a type ID CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IE CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is an IF CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type IU CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type II CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type III CRISPR-Cas system.
[0052] In some embodiments, processing of CRISPR arrays disclosed herein includes, but is not limited to, the following processes: 1) transcription of nucleic acids encoding pre-crRNAs, 2) recognition of cascades and / or specific members of cascades, such as Cas6, and 3) processing of pre-crRNAs into mature crRNAs by cascades and / or specific members of cascades, such as Cas6. In some embodiments, the mode of action in Type I CRISPR systems includes, but is not limited to, the following processes: 4) mature crRNA complex formation with cascades, 5) target recognition by the complexed mature crRNA / cascade complex, and 6) nuclease activity at the target, resulting in DNA degradation.
[0053] In some embodiments, components of a CRISPR-Cas system and bacteriophages comprising the CRISPR-Cas system components are provided herein. For example, a nucleic acid sequence is provided herein that comprises at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 83-87. Optionally, the nucleic acid sequence comprises at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 83. Optionally, the nucleic acid sequence comprises at least about 80%, 81%, 82%, 84%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 84. Optionally, the nucleic acid sequence comprises at least about 80%, 81%, 82%, 85%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:85. Optionally, the nucleic acid sequence comprises at least about 80%, 81%, 82%, 86%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 86. Optionally, the nucleic acid sequence comprises at least about 80%, 81%, 82%, 87%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 87. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 83. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 84. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 85. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 86. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 87.In any of these embodiments, the nucleic acid sequence may comprise a sequence at least 90% identical to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In a non-limiting example, the nucleic acid sequence comprises one or more of SEQ ID NO: 12, SEQ ID NO: 16, and SEQ ID NO: 20.
[0054] Further provided herein are CRISPR-Cas system components comprising a nucleic acid sequence at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 24. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 24. In any of these embodiments, the nucleic acid sequence may comprise a sequence at least 90% identical to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In a non-limiting example, the nucleic acid sequence comprises one or more of SEQ ID NO: 12, SEQ ID NO: 16, and SEQ ID NO: 20.
[0055] Provided herein are CRISPR-Cas system components comprising at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 25. Optionally, the nucleic acid sequence comprises at least about 90% identity to SEQ ID NO: 25. In any of these embodiments, the nucleic acid sequence may comprise a sequence at least 90% identical to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In a non-limiting example, the nucleic acid sequence comprises one or more of SEQ ID NO: 12, SEQ ID NO: 16, and SEQ ID NO: 20.
[0056] CRISPR phages In certain embodiments, disclosed herein are bacteriophage compositions comprising a CRISPR-Cas system and methods of use thereof.
[0057] Bacteriophages, or "phages," refer to a group of bacterial viruses engineered or sourced from environmental sources. Individual bacteriophages typically have a narrow host range, meaning that phages are highly specific to one or a few strains of a bacterial species; this specificity makes them unique in their antibacterial activity. Bacteriophages are bacterial viruses that rely on the host cell's machinery to replicate. Bacteriophages are generally classified as virulent or lysogenic phages depending on their lifestyle. Virulent phages, also known as lytic bacteriophages, can only undergo lytic replication. Lytic bacteriophages infect host cells and undergo multiple rounds of replication, causing cell lysis and the release of newly produced bacteriophage particles. In some embodiments, the lytic bacteriophages disclosed herein retain their replication ability. In some embodiments, the lytic bacteriophages disclosed herein retain their ability to induce cell lysis. In some embodiments, the lytic bacteriophage disclosed herein retain both its ability to replicate and induce cell lysis. In some embodiments, the bacteriophage disclosed herein comprises a CRISPR array. In some embodiments, the CRISPR array does not affect the bacteriophage's ability to replicate and / or induce cell lysis. A temperate or lysogenic bacteriophage can undergo lysogenization, where the phage ceases replication and resides stably within the host cell, either integrated into the bacterial genome or maintained as an extrachromosomal plasmid. A temperate phage can also undergo lytic replication similar to its lytic bacteriophage counterpart. Whether a temperate phage replicates by lysis or undergoes lysogenization after infection depends on various factors, including the growth conditions and physiological state of the cell. A bacterial cell in which a temperate phage has integrated into its genome is referred to as a lysogenic bacterium or lysogen. Exposure to adverse conditions can induce reactivation of temperate phage, terminating the lysogenic state and allowing the phage to resume lytic replication, a process called induction.Adverse conditions that result in the termination of the lysogenic state include starvation, exposure to UV or ionizing radiation, and exposure to mutagenic chemicals. This results in the expression of phage genes, reversal of the integration process, and lytic growth. In some embodiments, the temperate phage disclosed herein is rendered lytic. The term "lysogenization gene" refers to any gene whose product promotes lysogenization of a temperate phage. Lysogenization genes can do so directly, as in the case of an integrase protein, which facilitates integration of a bacteriophage into a host genome. Lysogenization genes can also promote lysogenization indirectly, as in the case of the CI transcription factor, which maintains lysogenization by preventing transcription of genes required for lytic replication.
[0058] Bacteriophages package and deliver synthetic DNA using three overall approaches. In the first approach, the synthetic DNA is reassembled into the bacteriophage genome in a targeted manner, usually involving a selectable marker. In the second approach, restriction sites within the phage are used to introduce the synthetic DNA in vitro. In the third approach, a plasmid that collectively encodes the phage packaging site and origin of replication for cell lysis is packaged as part of the assembly of the bacteriophage particle. The resulting plasmid is a coined "phagemid."
[0059] Phages are restricted to a given strain of bacteria for developmental reasons. In some cases, injecting their genetic material into an incompatible strain would be counterproductive. Therefore, phages evolved to specifically infect a restricted cross-section of bacterial strains. However, some phages have been shown to inject their genetic material into a wide range of bacteria. A typical example is phage P1, which has been shown to inject DNA into a range of Gram-negative bacteria.
[0060] The capacity of phage capsids is limited, meaning that their genome size must be kept within a strict range for proper packaging. Because the DNA encoding the Cas operon + CRISPR array is large (total of about 6000 bp), other DNA must be removed from the phage genome to make room for the Cas system. The exemplary phage engineered herein contains a Cas operon and CRISPR array inserted into the phage so that the phage retains viability.
[0061] Disclosed herein in some embodiments is a bacteriophage comprising a first spacer sequence or a first nucleic acid sequence encoding a crRNA transcribed therefrom, wherein the first spacer sequence is complementary to a target nucleotide sequence from a target gene in Pseudomonas species. In some embodiments, the bacteriophage comprises a first spacer sequence or a first nucleic acid sequence encoding a crRNA transcribed therefrom, wherein the first spacer sequence is complementary to a target nucleotide sequence from a target gene in Pseudomonas species, provided that the bacteriophage is rendered lytic. In some embodiments, the bacteriophage is a temperate bacteriophage. In some embodiments, the bacteriophage is rendered lytic by removal, replacement, or inactivation of a lysogenic gene. In some embodiments, the lysogenic gene plays a role in maintaining the lysogenic cycle in the bacteriophage. In some embodiments, the lysogenic gene plays a role in establishing the lysogenic cycle in the bacteriophage. In some embodiments, a lysogen gene plays a role in both establishing the lysogenic cycle and maintaining the lysogenic cycle in a bacteriophage. In some embodiments, the lysogen gene is a repressor gene. In some embodiments, the lysogen gene is a cI repressor gene. In some embodiments, a bacteriophage is rendered lytic by removal of a regulatory element of the lysogen gene. In some embodiments, a bacteriophage is rendered lytic by removal of a promoter of the lysogen gene. In some embodiments, a bacteriophage is rendered lytic by removal of a functional element of the lysogen gene. In some embodiments, the lysogen gene is an activator gene. In some embodiments, the lysogen gene is a cII gene. In some embodiments, the lysogen gene is a lexA gene. In some embodiments, the lysogen gene is an int (integrase) gene. In some embodiments, two or more lysogen genes are removed, replaced, or inactivated to result in blockage of the bacteriophage lysogenic cycle and / or induction of the lytic cycle.In some embodiments, the bacteriophage is rendered lytic via a second CRISPR array comprising a second spacer directed to a lysogeny gene. In some embodiments, the bacteriophage is rendered lytic by insertion of one or more lytic genes. In some embodiments, the bacteriophage is rendered lytic by insertion of one or more genes that contribute to the induction of the lytic cycle. In some embodiments, the bacteriophage is rendered lytic by modifying the expression of one or more genes that contribute to the induction of the lytic cycle. In some embodiments, the bacteriophage is phenotypically altered from a lysogenic bacteriophage to a lytic bacteriophage. In some embodiments, the phenotypic change is achieved via a self-targeting CRISPR-Cas system to render the bacteriophage lytic due to its inability to lysogenize. In some embodiments, the self-targeting CRISPR-Cas includes a self-targeting crRNA from the prophage genome and kills the lysogen. In some embodiments, the bacteriophage is rendered lytic by environmental modification. In some embodiments, environmental modifications include, but are not limited to, temperature, pH, or nutrient modification, exposure to antibiotics, hydrogen peroxide, exogenous DNA, or DNA damaging agents, the presence of organic carbon, and heavy metals (e.g., in the form of chromium(VI)). In some embodiments, the lytically rendered bacteriophage is prevented from reverting to a lysogenic state. In some embodiments, the lytically rendered bacteriophage is prevented from reverting to a lysogenic state by the introduction of an additional CRISPR array. In some embodiments, the bacteriophage does not confer any additional properties on the Pseudomonas species beyond causing cell death due to the lytic activity of the bacteriophage and / or the activity of the CRISPR array.
[0062] Further disclosed herein in some embodiments is a temperate bacteriophage comprising a first nucleic acid sequence encoding a first spacer sequence or a crRNA transcribed therefrom, wherein the first spacer sequence is complementary to a target nucleotide sequence from a target gene in Pseudomonas species, provided the bacteriophage is lytic. In some embodiments, the bacteriophage infects multiple bacterial strains. In some embodiments, the target nucleotide sequence comprises all or a portion of a promoter sequence for the target gene. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding strand of a transcribed region of the target gene. In some embodiments, the target nucleotide sequence comprises at least a portion of an essential gene required for survival of the Pseudomonas species. In some embodiments, the target nucleotide sequence comprises a highly conserved non-coding or intergenic sequence. In some embodiments, the target sequence is an intergenic sequence between the essential gene rpmF and a conserved hypothetical protein. In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the essential gene is dnaA, ftsA, gyrB, dnaN, glnS, or rpoB. In some embodiments, the target sequence is PA4325 (hypothetical protein), PA1310 (phnW, pyruvate aminotransferase), or the boundary between PA2970 (rpmF, 50S ribosomal protein L32) and PA2971 (conserved hypothetical protein). In some embodiments, the target nucleotide sequence is in a non-essential gene.In some embodiments, the target nucleotide sequence is a non-coding sequence. In some embodiments, the non-coding sequence is an intergenic sequence. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence of a highly conserved sequence in Pseudomonas species. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence of a sequence in Pseudomonas species. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence comprising all or a portion of a promoter sequence of an essential gene. In some embodiments, the first nucleic acid sequence comprises a first CRISPR array comprising at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to the first spacer sequence at either its 5' end or 3' end.
[0063] In some embodiments, the bacteriophage DNA is from a temperate or lysogenic bacteriophage, including, but not limited to, p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4209, p4430, or PB1, or two or more thereof.
[0064] In some embodiments, the bacteriophage of interest is obtained from an environmental source or a market research supplier. In some embodiments, the obtained bacteriophage is screened against a library of bacteria and its related strains for lytic activity. In some embodiments, the bacteriophage is screened against a library of bacteria and its related strains for the ability to generate primary resistance in the screened bacteria.
[0065] In some embodiments, the nucleic acid is inserted into a bacteriophage genome. In some embodiments, the nucleic acid comprises a crArray, a Cas system, or a combination thereof. In some embodiments, the nucleic acid is inserted into a bacteriophage genome at a transcription terminator site at the end of an operon of interest. In some embodiments, the nucleic acid is inserted into a bacteriophage genome in place of one or more removed non-essential genes. In some embodiments, the nucleic acid is inserted into a bacteriophage genome in place of one or more removed lysogenic genes. In some embodiments, replacement of non-essential and / or lysogenic genes with the nucleic acid enhances the lytic activity of the bacteriophage. In some embodiments, replacement of non-essential and / or lysogenic genes with the nucleic acid confers lytic properties to a lysogenic bacteriophage.
[0066] In some embodiments, a nucleic acid is introduced into a bacteriophage genome at a first location, while one or more nonessential and / or lysogenic genes are separately removed and / or inactivated from the bacteriophage genome at a separate location. In some embodiments, removal of one or more nonessential and / or lysogenic genes renders a lysogenic bacteriophage a lytic bacteriophage. Similarly, in some embodiments, one or more lytic genes are introduced into a bacteriophage to render a non-lytic, lysogenic bacteriophage a lytic bacteriophage.
[0067] In some embodiments, replacement, excision, inactivation, or any combination thereof, of one or more non-essential and / or lysogenic genes is achieved by chemical, biochemical, and / or any suitable method, hi some embodiments, insertion of one or more lytic genes is achieved by any suitable chemical, biochemical, and / or physical method by homologous recombination.
[0068] In some embodiments, the non-essential genes to be removed and / or replaced from the bacteriophage are genes that are not essential for the viability of the bacteriophage, hi some embodiments, the non-essential genes to be removed and / or replaced from the bacteriophage are genes that are not essential for the induction and / or maintenance of the lytic cycle.
[0069] In certain embodiments herein, a bacteriophage is disclosed that comprises a complete exogenous CRISPR-Cas system. In some embodiments, the CRISPR-Cas system is a type I CRISPR-Cas system, a type II CRISPR-Cas system, a type III CRISPR-Cas system, a type IV CRISPR-Cas system, a type V CRISPR-Cas system, or a type VI CRISPR-Cas system. In certain embodiments herein, a bacteriophage is disclosed that comprises a nucleic acid sequence encoding a type I CRISPR-Cas system, comprising (a) a CRISPR array, (b) a cascade polypeptide, and (c) a Cas3 polypeptide. In some embodiments, the CRISPR-Cas system comprises at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:24. In some embodiments, the CRISPR-Cas system comprises at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:25.
[0070] In some embodiments, the bacteriophage is p1106 (ATCC Deposit No. PTA-127024), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p1587 (ATCC Deposit No. PTA-127027), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p1772 (ATCC Deposit No. PTA-127030), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p1835 (ATCC Deposit No. PTA-127032), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2037 (ATCC Deposit No. PTA-127034), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2131 (ATCC Deposit No. PTA-127036), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2132 (ATCC Deposit No. PTA-127038), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2363 (ATCC Deposit No. PTA-127041), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2421 (ATCC Deposit No. PTA-127043), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is p2973 (ATCC Deposit No. PTA-127045), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage is PB1 (ATCC Deposit No. PTA-127049), and the bacteriophage comprises a Type I CRISPR-Cas system. In some embodiments, the bacteriophage comprises a phage listed in Table 1A.
[0071] In some embodiments, the bacteriophage comprises a CRISPR-system having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 24. In some embodiments, the bacteriophage comprises a CRISPR-system having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 25.
[0072] In some embodiments, the bacteriophage is p1106e003 (ATCC Deposit No. PTA-127023) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p1106e003. In some embodiments, the bacteriophage is p1587e002 (ATCC Deposit No. PTA-127026) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p1587e002. In some embodiments, the bacteriophage is p1772e005 (ATCC Deposit No. PTA-127029) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p1772e005. In some embodiments, the bacteriophage is p1835e002 (ATCC Deposit No. PTA-127031) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p1835e002. In some embodiments, the bacteriophage is p2037e002 (ATCC Deposit No. PTA-127033) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2037e002. In some embodiments, the bacteriophage is p2131e002 (ATCC Deposit No. PTA-127035) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2131e002.In some embodiments, the bacteriophage is p2132e002 (ATCC Deposit No. PTA-127037) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2132e002. In some embodiments, the bacteriophage is p2363e003 (ATCC Deposit No. PTA-127040) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2363e003. In some embodiments, the bacteriophage is p2421e002 (ATCC Deposit No. PTA-127042) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2421e002. In some embodiments, the bacteriophage is p2973e002 (ATCC Deposit No. PTA-127044) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to p2973e002. In some embodiments, the bacteriophage is PB1e002 (ATCC Deposit No. PTA-127048) or is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to PB1e002. In some embodiments, the bacteriophage comprises a phage listed in Table 1A. In some embodiments, a bacteriophage cocktail system is provided comprising one or more engineered bacteriophages and a wild-type phage. In some embodiments, the wild-type phage is a phage of Table 5A, Table 5B, or Table 6A.In some embodiments, the wild-type phage is a wild-type Pbuna virus. Non-limiting examples of wild-type Pbuna viruses include p1106, p1587, p1835, p2037, p2363, p2421, and pb1. In some embodiments, the wild-type phage is a wild-type Samuna virus. Non-limiting examples of wild-type Samuna viruses include p1772, p2121, p2132, and p2973. In some embodiments, the wild-type phage is a wild-type Nankoku virus. In some embodiments, the wild-type phage is a wild-type PhiKZ virus. Non-limiting examples of wild-type PhiKZ viruses include p1194p.b008 and p4430. In some embodiments, the wild-type phage is a wild-type PhiKMV virus. A non-limiting example of a wild-type PhiKMV virus is p2167. In some embodiments, the wild-type phage is a wild-type Bruynoghe virus. Non-limiting examples of wild-type Bruynoghe viruses include p1695 and p3278. In some embodiments, the wild-type phage is p1194. In some embodiments, the wild-type phage is p4430. In some embodiments, the wild-type phage is p1695. In some embodiments, the wild-type phage is a PhiKZ virus, a PhiKMV virus, a Brunyoghe virus, a Samuna virus, a Nankoku virus, an Abidjan virus, a Baikal virus, a Beetre virus, a Casadaban virus, a Citex virus, a Cystovirus, a Detre virus, an El virus, a Holloway virus, a Kochitakasu virus, a Lituna virus, a Luzseptima virus, a Nipuna virus, a Pakpuna virus, a Pamex virus, a Paundecim virus, a Phitre virus, a Primolici virus, a Septimatre virus, a Stubbur virus, a Tertilici virus, a Yua virus, a Zicotria virus, or a Pbuna virus.
[0073] In some embodiments, the bacteriophage cocktail system comprises CK000512 (p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695).
[0074] In some embodiments, multiple bacteriophages are used together. In some embodiments, the multiple bacteriophages used together target the same or different bacteria in a sample or subject. In some embodiments, a cocktail comprising multiple bacteriophages is used together. In some embodiments, the cocktail comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 phages selected from Table 1A. In some embodiments, the cocktail comprises two phages selected from Table 1A. In some embodiments, the cocktail comprises three phages selected from Table 1A. In some embodiments, the cocktail comprises three phages selected from Table 1A. In some embodiments, the cocktail comprises four phages selected from Table 1A. In some embodiments, the cocktail comprises five phages selected from Table 1A. In some embodiments, the cocktail comprises six phages selected from Table 1A. In some embodiments, the cocktail comprises a cocktail selected from Table 6A. In some embodiments, at least one bacteriophage in the cocktail comprises a CRISPR array. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a CRISPR array. In some embodiments, at least one bacteriophage in the cocktail comprises a nucleic acid sequence encoding a cascade polypeptide. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a nucleic acid sequence encoding a cascade polypeptide. In some embodiments, at least one bacteriophage in the cocktail comprises a nucleic acid sequence encoding a Cas3 polypeptide.In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a nucleic acid sequence encoding a Cas3 polypeptide. In some embodiments, the cocktail comprises p1106e003, p1835e002, p1772e005, and p2131e002. In some embodiments, the cocktail further comprises p1194. In some embodiments, the cocktail further comprises p1695. In some embodiments, the cocktail further comprises p4430. In some embodiments, the cocktail comprises p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the cocktail comprises p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695.
[0075] In some embodiments, a PhiKZ virus bacteriophage is provided herein that includes a type I CRISPR-Cas system. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR-Cas system includes one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences include at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array includes at least one repeat sequence that includes at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further includes a promoter sequence, e.g., selected from SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs:83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO:80), a Cas8c polypeptide (optionally SEQ ID NO:81), and a Cas7 polypeptide (optionally SEQ ID NO:82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:25.
[0076] In some embodiments, a PhiKMV virus bacteriophage is provided herein that includes a type I CRISPR-Cas system. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR-Cas system includes one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences include at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array includes at least one repeat sequence that includes at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further includes a promoter sequence, e.g., selected from SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs:83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO:80), a Cas8c polypeptide (optionally SEQ ID NO:81), and a Cas7 polypeptide (optionally SEQ ID NO:82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:25.
[0077] In some embodiments, provided herein is a Brunyoghe virus bacteriophage comprising a type I CRISPR-Cas system. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR-Cas system comprises one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array comprises at least one repeat sequence comprising at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further comprises a promoter sequence, e.g., selected from SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs:83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO:80), a Cas8c polypeptide (optionally SEQ ID NO:81), and a Cas7 polypeptide (optionally SEQ ID NO:82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:25.
[0078] In some embodiments, a Samuna virus bacteriophage is provided herein that includes a type I CRISPR-Cas system. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR-Cas system includes one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences include at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array includes at least one repeat sequence that includes at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further includes a promoter sequence, e.g., selected from SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs:83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO:80), a Cas8c polypeptide (optionally SEQ ID NO:81), and a Cas7 polypeptide (optionally SEQ ID NO:82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO:25.
[0079] In some embodiments, provided herein are Pbuna virus bacteriophages comprising a type I CRISPR-Cas system. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR-Cas system comprises one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array comprises at least one repeat sequence comprising at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further comprises a promoter sequence, e.g., selected from SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 25.
[0080] Some embodiments herein provide a Nankoku virus bacteriophage comprising a type I CRISPR-Cas system. In some embodiments, the CRISPR-Cas system comprises one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOS: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOS: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array comprises at least one repeat sequence comprising at least about 90% sequence identity to any one of SEQ ID NOS: 26-30. In some embodiments, the nucleic acid sequence further comprises a promoter sequence, e.g., selected from SEQ ID NOS: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOS: 83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 25.
[0081] In some embodiments, a bacteriophage of Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimtre virus, Stubbur virus, Tertilici virus, Yua virus, or Zicotria virus is provided, comprising a Type I CRISPR-Cas system. In some embodiments, the CRISPR-Cas system comprises one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species, a Cascade polypeptide, and a Cas3 polypeptide. In some embodiments, the one or more spacer sequences comprise at least one of SEQ ID NOs: 12-23, 31-74, or 88-120, or at least 90% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array comprises at least one repeat sequence that comprises at least about 90% sequence identity to any one of SEQ ID NOs: 26-30. In some embodiments, the nucleic acid sequence further comprises a promoter sequence selected from, for example, SEQ ID NOs: 1-11. In some embodiments, the CRISPR array comprises at least about 90% sequence identity to a sequence set forth in Figures 1A-1E, or SEQ ID NOs: 83-87. In some embodiments, the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (a Type IC CRISPR-Cas system). In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 24. In some embodiments, the bacteriophage comprises a CRISPR system having at least 90% identity to SEQ ID NO: 25.
[0082] CRISPR arrays In some embodiments, the CRISPR array (crArray) comprises a spacer sequence and at least one repeat sequence. In some embodiments, the CRISPR array encodes a processed mature crRNA. In some embodiments, the mature crRNA is introduced into a phage or a Pseudomonas species. In some embodiments, an endogenous or exogenous Cas6 processes the CRISPR array into a mature crRNA. In some embodiments, the exogenous Cas6 is introduced into a phage. In some embodiments, the phage comprises an exogenous Cas6. In some embodiments, the exogenous Cas6 is introduced into a Pseudomonas species.
[0083] In some embodiments, the CRISPR array comprises a spacer sequence. In some embodiments, the CRISPR array further comprises at least one repeat sequence. In some embodiments, the at least one repeat sequence is operably linked to the spacer sequence at either its 5' or 3' end. In some embodiments, the CRISPR array is of any length and comprises any number of spacer nucleotide sequences alternating with repeat nucleotide sequences necessary to achieve a desired level of Pseudomonas species kill by targeting one or more essential genes. In some embodiments, the CRISPR array comprises, consists essentially of, or consists of from 1 to about 100 spacer nucleotide sequences, linked to repeat nucleotide sequences on their 5' and 3' ends, respectively. In some embodiments, the CRISPR array comprises: , 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more spacer nucleotide sequences.
[0084] In some embodiments, the CRISPR array comprises a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 83. In some embodiments, the CRISPR array comprises a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:84. In some embodiments, the CRISPR array comprises a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 85. In some embodiments, the CRISPR array comprises a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:86. In some embodiments, the CRISPR array comprises a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 87. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973.In some embodiments, the CRISPR array is engineered into the Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into the Nankoku virus. In some embodiments, the CRISPR array is engineered into the Abidjan virus. In some embodiments, the CRISPR array is engineered into the Baikal virus. In some embodiments, the CRISPR array is engineered into the Beetre virus. In some embodiments, the CRISPR array is engineered into the Casadaban virus. In some embodiments, the CRISPR array is engineered into the Citex virus. In some embodiments, the CRISPR array is engineered into the Cysto virus. In some embodiments, the CRISPR array is engineered into the Detre virus. In some embodiments, the CRISPR array is engineered into the El virus. In some embodiments, the CRISPR array is engineered into the Holloway virus. In some embodiments, the CRISPR array is engineered into Kochitakasu virus. In some embodiments, the CRISPR array is engineered into Lituna virus. In some embodiments, the CRISPR array is engineered into Luzseptima virus. In some embodiments, the CRISPR array is engineered into Nipuna virus. In some embodiments, the CRISPR array is engineered into Pakpuna virus. In some embodiments, the CRISPR array is engineered into Pamex virus. In some embodiments, the CRISPR array is engineered into Paundecim virus. In some embodiments, the CRISPR array is engineered into Phitre virus. In some embodiments, the CRISPR array is engineered into Primolici virus. In some embodiments, the CRISPR array is engineered into Septimatre virus. In some embodiments, the CRISPR array is engineered into Stubbur virus.In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0085] Spacer sequence In some embodiments, the spacer sequence is complementary to a target nucleotide sequence in Pseudomonas species. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence in Pseudomonas aeruginosa. In some embodiments, the target nucleotide sequence is a non-coding region. In some embodiments, the coding region is an essential gene. In some embodiments, the coding region is a non-essential gene. In some embodiments, the target nucleotide sequence is a non-coding sequence. In some embodiments, the non-coding sequence is an intergenic sequence. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence of a highly conserved sequence in Pseudomonas species. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence of a sequence in Pseudomonas species. In some embodiments, the spacer sequence is complementary to a target nucleotide sequence comprising all or a portion of a promoter sequence of an essential gene. In some embodiments, the spacer sequence comprises 1, 2, 3, 4, or 5 mismatches compared to the target nucleotide sequence. In some embodiments, the mismatches are consecutive. In some embodiments, the mismatches are non-consecutive. In some embodiments, the spacer sequence has 70% complementarity to the target nucleotide sequence. In some embodiments, the spacer sequence is 80% complementary to the target nucleotide sequence. In some embodiments, the spacer sequence is 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to the target nucleotide sequence. In some embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence. In some embodiments, the spacer sequence is fully complementary or substantially complementary over a region of the target nucleotide sequence that is at least about 8 nucleotides to about 150 nucleotides in length. In some embodiments, the spacer sequence is fully complementary or substantially complementary over a region of the target nucleotide sequence that is at least about 20 nucleotides to about 100 nucleotides in length.In some embodiments, the 5' region of the spacer sequence is 100% complementary to the target nucleotide sequence, while the 3' region of the spacer is substantially complementary to the target nucleotide sequence, such that the overall complementarity of the spacer sequence to the target nucleotide sequence is less than 100%. For example, in some embodiments, the first 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides in the 3' region of a 20-nucleotide spacer sequence (seed region) are 100% complementary to the target nucleotide sequence, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleotide sequence. In some embodiments, the first 7-12 nucleotides at the 3' end of the spacer sequence are 100% complementary to the target nucleotide sequence, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary to the target nucleotide sequence (e.g., 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more complementary). In some embodiments, the first 7-10 nucleotides at the 3' end of the spacer sequence are 75% to 99% complementary to the target nucleotide sequence, while the remaining nucleotides in the 5' region of the spacer sequence are at least about 50% to about 99% complementary to the target nucleotide sequence. In some embodiments, the first 7-10 nucleotides at the 3' end of the spacer sequence are 100% complementary to the target nucleotide sequence, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleotide sequence. In some embodiments, the first 10 nucleotides (within the seed region) of the spacer sequence are 100% complementary to the target nucleotide sequence, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleotide sequence.In some embodiments, the 5' region of the spacer sequence (e.g., the first 8 nucleotides at the 5' end, the first 10 nucleotides at the 5' end, the first 15 nucleotides at the 5' end, the first 20 nucleotides at the 5' end) has about 75% or more complementarity to the target nucleotide sequence (75% to about 100% complementarity), while the remainder of the spacer sequence has about 50% or more complementarity to the target nucleotide sequence. In some embodiments, the first 8 nucleotides at the 5' end of the spacer sequence have 100% complementarity to the target nucleotide sequence or have one or two mutations such that they are about 88% complementary or about 75% complementary to the target nucleotide sequence, respectively, while the remainder of the spacer nucleotide sequence is at least about 50% complementary to the target nucleotide sequence.
[0086] In some embodiments, the spacer sequence is from about 15 nucleotides to about 150 nucleotides in length. In some embodiments, the spacer nucleotide sequence is from about 15 nucleotides to about 100 nucleotides in length (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, , 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides).In some embodiments, the spacer nucleotide sequence is from about 8 to about 150 nucleotides, from about 8 to about 100 nucleotides, from about 8 to about 50 nucleotides, from about 8 to about 40 nucleotides, from about 8 to about 30 nucleotides, from about 8 to about 25 nucleotides, from about 8 to about 20 nucleotides, from about 10 to about 150 nucleotides, from about 10 to about 100 nucleotides, from about 10 to about 80 nucleotides, from about 10 to about 50 nucleotides, from about 10 to about 40 nucleotides, from about 10 to about 30 nucleotides, from about 10 to about 25 nucleotides, from about 10 to about 20 nucleotides, from about 15 to about 150 nucleotides, from about 15 to about 100 nucleotides, from about 15 to about 50 nucleotides, from about 15 to about 40 nucleotides, from about 15 to about 30 nucleotides, nucleotides, about 20 to about 100 nucleotides, about 20 to about 80 nucleotides, about 20 to about 50 nucleotides, about 20 to about 40 nucleotides, about 20 to about 30 nucleotides, about 20 to about 25 nucleotides, at least about 8, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 32, at least about 35, at least about 40, at least 44, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 110, at least about 120, at least about 130, at least about 140, at least about 150 or more nucleotides, and any value or range therein. In some embodiments, the P. aeruginosa type IC Cas system has a spacer length of about 30 to 39 nucleotides, about 31 to about 38 nucleotides, about 32 to about 37 nucleotides, about 33 to about 36 nucleotides, about 34 to about 35 nucleotides, or about 35 nucleotides. In some embodiments, the P. aeruginosa type IC Cas system has a spacer length of about 34 nucleotides.In some embodiments, the P. aeruginosa type IC Cas system has a spacer length of at least about 10, at least about 15, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 29, at least 29, at least about 30, at least about 31, at least about 32, at least about 33, at least 34, at least about 35, at least about 36, at least about 37, at least about 38, at least about 39, at least about 20, at least about 41, at least about 42, at least about 43, at least about 44, at least about 45, or greater than about 45 nucleotides.
[0087] In some embodiments, the spacer sequence comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some examples, the spacer sequence comprises at least or about 95% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some examples, the spacer sequence comprises at least or about 97% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some examples, the spacer sequence comprises at least or about 99% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some examples, the spacer sequence comprises 100% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, 88-120. In some examples, the spacer sequence comprises at least a portion having at least or about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or more than 34 nucleotides of any one of SEQ ID NOs: 12-23, 31-74, 88-120.
[0088] The term "sequence identity" means that two polynucleotide sequences are identical (nucleotide by nucleotide) over a comparison window. The term "percent sequence identity" is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions where the same nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage sequence identity.
[0089] The term "homology" or "similarity" between two proteins is determined by comparing the amino acid sequence and conserved amino acid substitutes of one protein sequence with that of another protein sequence. Similarity may be determined by procedures well known in the art, for example, the BLAST program (Basic Local Alignment Search Tool of the National Center for Biological Information).
[0090] In some embodiments, the identities of two or more spacer sequences in a CRISPR array are the same. In some embodiments, the identities of two or more spacer sequences in a CRISPR array are different. In some embodiments, the identities of two or more spacer sequences in a CRISPR array are different but complementary to one or more target nucleotide sequences. In some embodiments, the identities of two or more spacer sequences in a CRISPR array are different and complementary to one or more target nucleotide sequences that are overlapping sequences. In some embodiments, the identities of two or more spacer sequences in a CRISPR array are different and complementary to one or more target nucleotide sequences that are not overlapping sequences. In some embodiments, the target nucleotide sequence is about 10 to 40 contiguous nucleotides in length located immediately adjacent to a PAM sequence (a PAM sequence located immediately 3' of the target region) in the genome of the organism. In some embodiments, the target nucleotide sequence is adjacent to or located next to a PAM (protospacer adjacent motif). In some embodiments, two or more sequences of the CRISPR array comprise at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, two or more sequences of the CRISPR array comprise at least or about 95% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, two or more sequences of the CRISPR array comprise at least or about 97% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, two or more sequences of the CRISPR array comprise at least or about 99% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, two or more sequences of the CRISPR array comprise 100% sequence identity to any one of SEQ ID NOs: 12-23, 31-74, or 88-120.In some embodiments, two or more sequences of the CRISPR array comprise at least a portion having at least or about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or more than 34 nucleotides of any one of SEQ ID NOs: 12-23, 31-74, or 88-120. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into a Nankoku virus. In some embodiments, the CRISPR array is engineered into an Abidjan virus. In some embodiments, the CRISPR array is engineered into a Baikal virus. In some embodiments, the CRISPR array is engineered into a Beetre virus. In some embodiments, the CRISPR array is engineered into a Casadaban virus. In some embodiments, the CRISPR array is engineered into a Citex virus. In some embodiments, the CRISPR array is engineered into a Cysto virus. In some embodiments, the CRISPR array is engineered into a Detre virus. In some embodiments, the CRISPR array is engineered into an El virus.In some embodiments, the CRISPR array is engineered into Holloway virus. In some embodiments, the CRISPR array is engineered into Kochitakasu virus. In some embodiments, the CRISPR array is engineered into Lituna virus. In some embodiments, the CRISPR array is engineered into Luzseptima virus. In some embodiments, the CRISPR array is engineered into Nipuna virus. In some embodiments, the CRISPR array is engineered into Pakpuna virus. In some embodiments, the CRISPR array is engineered into Pamex virus. In some embodiments, the CRISPR array is engineered into Paundecim virus. In some embodiments, the CRISPR array is engineered into Phitre virus. In some embodiments, the CRISPR array is engineered into Primolici virus. In some embodiments, the CRISPR array is engineered into Septimtre virus. In some embodiments, the CRISPR array is engineered into Stubbur virus. In some embodiments, the CRISPR array is engineered into Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0091] In some embodiments, the CRISPR array comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 12-15, and a second spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 16-19. and a third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 20-23, wherein the first spacer sequence, second spacer sequence, and third spacer sequence comprise 0-8 nucleotide modifications. In some examples, the first spacer sequence comprises at least or about 97% homology to any one of SEQ ID NOs: 12-15, the second spacer sequence comprises at least or about 97% homology to any one of SEQ ID NOs: 16-19, and the third spacer sequence comprises at least or about 97% homology to any one of SEQ ID NOs: 20-23. In some examples, the first spacer sequence comprises at least or about 99% homology to any one of SEQ ID NOs: 12-15, the second spacer sequence comprises at least or about 99% homology to any one of SEQ ID NOs: 16-19, and the third spacer sequence comprises at least or about 99% homology to any one of SEQ ID NOs: 20-23. In some examples, the first spacer sequence comprises at least or about 100% homology to any one of SEQ ID NOs: 12-15, the second spacer sequence comprises at least or about 100% homology to any one of SEQ ID NOs: 16-19, and the third spacer sequence comprises at least or about 100% homology to any one of SEQ ID NOs: 20-23. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430.In some embodiments, the CRISPR array is engineered into the PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into the Brunyoghe virus. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into the Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into the Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into the Nankoku virus. In some embodiments, the CRISPR array is engineered into the Abidjan virus. In some embodiments, the CRISPR array is engineered into Baikal virus. In some embodiments, the CRISPR array is engineered into Beetre virus. In some embodiments, the CRISPR array is engineered into Casadaban virus. In some embodiments, the CRISPR array is engineered into Citex virus. In some embodiments, the CRISPR array is engineered into Cysto virus. In some embodiments, the CRISPR array is engineered into Detre virus. In some embodiments, the CRISPR array is engineered into El virus. In some embodiments, the CRISPR array is engineered into Holloway virus. In some embodiments, the CRISPR array is engineered into Kochitakasu virus. In some embodiments, the CRISPR array is engineered into Lituna virus. In some embodiments, the CRISPR array is engineered into Luzseptima virus. In some embodiments, the CRISPR array is engineered into Nipuna virus. In some embodiments, the CRISPR array is engineered into Pakpuna virus.In some embodiments, the CRISPR array is engineered into a Pamex virus. In some embodiments, the CRISPR array is engineered into a Paundecim virus. In some embodiments, the CRISPR array is engineered into a Phitre virus. In some embodiments, the CRISPR array is engineered into a Primolici virus. In some embodiments, the CRISPR array is engineered into a Septimtre virus. In some embodiments, the CRISPR array is engineered into a Stubbur virus. In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0092] In some embodiments, the CRISPR array comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 12 and at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 16. and a third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:20, wherein the first spacer sequence, second spacer sequence, and third spacer sequence comprise 0-8 nucleotide modifications. In some examples, the first spacer sequence comprises at least or about 97% homology to SEQ ID NO:12, the second spacer sequence comprises at least or about 97% homology to SEQ ID NO:16, and the third spacer sequence comprises at least or about 97% homology to SEQ ID NO:20. In some examples, the first spacer sequence comprises at least or about 99% homology to SEQ ID NO: 12, the second spacer sequence comprises at least or about 99% homology to SEQ ID NO: 16, and the third spacer sequence comprises at least or about 99% homology to SEQ ID NO: 20. In some examples, the first spacer sequence comprises at least or about 100% homology to SEQ ID NO: 12, the second spacer sequence comprises at least or about 100% homology to SEQ ID NO: 16, and the third spacer sequence comprises at least or about 100% homology to SEQ ID NO: 20. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus.In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into a Nankoku virus. In some embodiments, the CRISPR array is engineered into an Abidjan virus. In some embodiments, the CRISPR array is engineered into a Baikal virus. In some embodiments, the CRISPR array is engineered into a Beetre virus. In some embodiments, the CRISPR array is engineered into a Casadaban virus. In some embodiments, the CRISPR array is engineered into the Citex virus. In some embodiments, the CRISPR array is engineered into the Cysto virus. In some embodiments, the CRISPR array is engineered into the Detre virus. In some embodiments, the CRISPR array is engineered into the El virus. In some embodiments, the CRISPR array is engineered into the Holloway virus. In some embodiments, the CRISPR array is engineered into the Kochitakasu virus. In some embodiments, the CRISPR array is engineered into the Lituna virus. In some embodiments, the CRISPR array is engineered into the Luzseptima virus. In some embodiments, the CRISPR array is engineered into the Nipuna virus. In some embodiments, the CRISPR array is engineered into the Pakpuna virus. In some embodiments, the CRISPR array is engineered into the Pamex virus. In some embodiments, the CRISPR array is engineered into the Paundecim virus. In some embodiments, the CRISPR array is engineered into the Phitre virus.In some embodiments, the CRISPR array is engineered into a Primolici virus. In some embodiments, the CRISPR array is engineered into a Septimatre virus. In some embodiments, the CRISPR array is engineered into a Stubbur virus. In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0093] In some embodiments, the CRISPR array comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 13 and at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 17. and a third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:21, wherein the first spacer sequence, second spacer sequence, and third spacer sequence comprise 0-8 nucleotide modifications. In some examples, the first spacer sequence comprises at least or about 97% homology to SEQ ID NO:13, the second spacer sequence comprises at least or about 97% homology to SEQ ID NO:17, and the third spacer sequence comprises at least or about 97% homology to SEQ ID NO:21. In some examples, the first spacer sequence comprises at least or about 99% homology to SEQ ID NO: 13, the second spacer sequence comprises at least or about 99% homology to SEQ ID NO: 17, and the third spacer sequence comprises at least or about 99% homology to SEQ ID NO: 21. In some examples, the first spacer sequence comprises at least or about 100% homology to SEQ ID NO: 13, the second spacer sequence comprises at least or about 100% homology to SEQ ID NO: 17, and the third spacer sequence comprises at least or about 100% homology to SEQ ID NO: 21. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus.In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into a Nankoku virus. In some embodiments, the CRISPR array is engineered into an Abidjan virus. In some embodiments, the CRISPR array is engineered into a Baikal virus. In some embodiments, the CRISPR array is engineered into a Beetre virus. In some embodiments, the CRISPR array is engineered into a Casadaban virus. In some embodiments, the CRISPR array is engineered into the Citex virus. In some embodiments, the CRISPR array is engineered into the Cysto virus. In some embodiments, the CRISPR array is engineered into the Detre virus. In some embodiments, the CRISPR array is engineered into the El virus. In some embodiments, the CRISPR array is engineered into the Holloway virus. In some embodiments, the CRISPR array is engineered into the Kochitakasu virus. In some embodiments, the CRISPR array is engineered into the Lituna virus. In some embodiments, the CRISPR array is engineered into the Luzseptima virus. In some embodiments, the CRISPR array is engineered into the Nipuna virus. In some embodiments, the CRISPR array is engineered into the Pakpuna virus. In some embodiments, the CRISPR array is engineered into the Pamex virus. In some embodiments, the CRISPR array is engineered into the Paundecim virus. In some embodiments, the CRISPR array is engineered into the Phitre virus.In some embodiments, the CRISPR array is engineered into a Primolici virus. In some embodiments, the CRISPR array is engineered into a Septimatre virus. In some embodiments, the CRISPR array is engineered into a Stubbur virus. In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0094] In some embodiments, the CRISPR array comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 14 and a second spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 18. and a third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:22, wherein the first spacer sequence, second spacer sequence, and third spacer sequence comprise 0-8 nucleotide modifications. In some examples, the first spacer sequence comprises at least or about 97% homology to SEQ ID NO:14, the second spacer sequence comprises at least or about 97% homology to SEQ ID NO:18, and the third spacer sequence comprises at least or about 97% homology to SEQ ID NO:22. In some examples, the first spacer sequence comprises at least or about 99% homology to SEQ ID NO: 14, the second spacer sequence comprises at least or about 99% homology to SEQ ID NO: 18, and the third spacer sequence comprises at least or about 99% homology to SEQ ID NO: 22. In some examples, the first spacer sequence comprises at least or about 100% homology to SEQ ID NO: 14, the second spacer sequence comprises at least or about 100% homology to SEQ ID NO: 18, and the third spacer sequence comprises at least or about 100% homology to SEQ ID NO: 22. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus.In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into a Nankoku virus. In some embodiments, the CRISPR array is engineered into an Abidjan virus. In some embodiments, the CRISPR array is engineered into a Baikal virus. In some embodiments, the CRISPR array is engineered into a Beetre virus. In some embodiments, the CRISPR array is engineered into a Casadaban virus. In some embodiments, the CRISPR array is engineered into the Citex virus. In some embodiments, the CRISPR array is engineered into the Cysto virus. In some embodiments, the CRISPR array is engineered into the Detre virus. In some embodiments, the CRISPR array is engineered into the El virus. In some embodiments, the CRISPR array is engineered into the Holloway virus. In some embodiments, the CRISPR array is engineered into the Kochitakasu virus. In some embodiments, the CRISPR array is engineered into the Lituna virus. In some embodiments, the CRISPR array is engineered into the Luzseptima virus. In some embodiments, the CRISPR array is engineered into the Nipuna virus. In some embodiments, the CRISPR array is engineered into the Pakpuna virus. In some embodiments, the CRISPR array is engineered into the Pamex virus. In some embodiments, the CRISPR array is engineered into the Paundecim virus. In some embodiments, the CRISPR array is engineered into the Phitre virus.In some embodiments, the CRISPR array is engineered into a Primolici virus. In some embodiments, the CRISPR array is engineered into a Septimatre virus. In some embodiments, the CRISPR array is engineered into a Stubbur virus. In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0095] In some embodiments, the CRISPR array comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 15 and a second spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 19. and a third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:23, wherein the first spacer sequence, second spacer sequence, and third spacer sequence comprise 0-8 nucleotide modifications. In some examples, the first spacer sequence comprises at least or about 97% homology to SEQ ID NO:15, the second spacer sequence comprises at least or about 97% homology to SEQ ID NO:19, and the third spacer sequence comprises at least or about 97% homology to SEQ ID NO:23. In some examples, the first spacer sequence comprises at least or about 99% homology to SEQ ID NO: 15, the second spacer sequence comprises at least or about 99% homology to SEQ ID NO: 19, and the third spacer sequence comprises at least or about 99% homology to SEQ ID NO: 23. In some examples, the first spacer sequence comprises at least or about 100% homology to SEQ ID NO: 15, the second spacer sequence comprises at least or about 100% homology to SEQ ID NO: 19, and the third spacer sequence comprises at least or about 100% homology to SEQ ID NO: 23. In some embodiments, the CRISPR array is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the CRISPR array is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the CRISPR array is engineered into a Brunyoghe virus.In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the CRISPR array is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the CRISPR array is engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the CRISPR array is engineered into a Nankoku virus. In some embodiments, the CRISPR array is engineered into an Abidjan virus. In some embodiments, the CRISPR array is engineered into a Baikal virus. In some embodiments, the CRISPR array is engineered into a Beetre virus. In some embodiments, the CRISPR array is engineered into a Casadaban virus. In some embodiments, the CRISPR array is engineered into the Citex virus. In some embodiments, the CRISPR array is engineered into the Cysto virus. In some embodiments, the CRISPR array is engineered into the Detre virus. In some embodiments, the CRISPR array is engineered into the El virus. In some embodiments, the CRISPR array is engineered into the Holloway virus. In some embodiments, the CRISPR array is engineered into the Kochitakasu virus. In some embodiments, the CRISPR array is engineered into the Lituna virus. In some embodiments, the CRISPR array is engineered into the Luzseptima virus. In some embodiments, the CRISPR array is engineered into the Nipuna virus. In some embodiments, the CRISPR array is engineered into the Pakpuna virus. In some embodiments, the CRISPR array is engineered into the Pamex virus. In some embodiments, the CRISPR array is engineered into the Paundecim virus. In some embodiments, the CRISPR array is engineered into the Phitre virus.In some embodiments, the CRISPR array is engineered into a Primolici virus. In some embodiments, the CRISPR array is engineered into a Septimatre virus. In some embodiments, the CRISPR array is engineered into a Stubbur virus. In some embodiments, the CRISPR array is engineered into a Tertilici virus. In some embodiments, the CRISPR array is engineered into a Yua virus. In some embodiments, the CRISPR array is engineered into a Zicotria virus.
[0096] In some embodiments, the spacers are multiplexed as clusters within one or more bacteriophages, e.g., engineered bacteriophages. The bacteriophage or bacteriophage cocktail comprises a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 12-15, and a second spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 16-19. , 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 20-23, and a second spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 20-23. In some embodiments, the bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 12 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 23. In some embodiments, the bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 13 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 22.In some embodiments, a bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 14 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 21. In some embodiments, the bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:15 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:20. In some embodiments, the bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 16 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 19. In some embodiments, the bacteriophage cocktail may include one or more arrays comprising a first spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 17 and a second or third spacer sequence comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 18.In some embodiments, multiple bacteriophages are used together. In some embodiments, the multiple bacteriophages used together target the same or different bacteria in a sample or subject. In some embodiments, a cocktail comprising multiple bacteriophages is used together. In some embodiments, the cocktail comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 phages selected from Table 1A. In some embodiments, the cocktail comprises two phages selected from Table 1A. In some embodiments, the cocktail comprises a wild-type or engineered PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the cocktail comprises a wild-type or engineered PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the cocktail comprises a wild-type or engineered Brunyoghe virus. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the cocktail comprises a wild-type or engineered Samunavirus virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, the cocktail comprises a wild-type or engineered Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, the cocktail comprises a wild-type or engineered Nankoku virus. In some embodiments, the cocktail comprises a wild-type or engineered Abidjan virus. In some embodiments, the cocktail comprises a wild-type or engineered Baikal virus. In some embodiments, the cocktail comprises a wild-type or engineered Beetre virus. In some embodiments, the cocktail comprises wild-type or engineered Casadaban virus.In some embodiments, the cocktail comprises a wild-type or engineered Citex virus. In some embodiments, the cocktail comprises a wild-type or engineered Cystovirus. In some embodiments, the cocktail comprises a wild-type or engineered Detre virus. In some embodiments, the cocktail comprises a wild-type or engineered El virus. In some embodiments, the cocktail comprises a wild-type or engineered Holloway virus. In some embodiments, the cocktail comprises a wild-type or engineered Kochitakasu virus. In some embodiments, the cocktail comprises a wild-type or engineered Lituna virus. In some embodiments, the cocktail comprises a wild-type or engineered Luzseptima virus. In some embodiments, the cocktail comprises a wild-type or engineered Nipuna virus. In some embodiments, the cocktail comprises a wild-type or engineered Pakpuna virus. In some embodiments, the cocktail comprises a wild-type or engineered Pamex virus. In some embodiments, the cocktail comprises a wild-type or engineered Paundecim virus. In some embodiments, the cocktail comprises a wild-type or engineered Phitre virus. In some embodiments, the cocktail comprises a wild-type or engineered Primolici virus. In some embodiments, the cocktail comprises a wild-type or engineered Septimatre virus. In some embodiments, the cocktail comprises a wild-type or engineered Stubbur virus. In some embodiments, the cocktail comprises a wild-type or engineered Tertilici virus. In some embodiments, the cocktail comprises a wild-type or engineered Yua virus. In some embodiments, the cocktail comprises a wild-type or engineered Zicotria virus.
[0097] In some embodiments, the cocktail comprises a cocktail selected from Table 6A. In some embodiments, at least one bacteriophage in the cocktail comprises a CRISPR array. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a CRISPR array. In some embodiments, at least one bacteriophage in the cocktail comprises a nucleic acid sequence encoding a cascade polypeptide. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a nucleic acid sequence encoding a cascade polypeptide. In some embodiments, at least one bacteriophage in the cocktail comprises a nucleic acid sequence encoding a Cas3 polypeptide. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 bacteriophages present in the cocktail comprise a nucleic acid sequence encoding a Cas3 polypeptide. In some embodiments, the cocktail comprises p1106e003, p1835e002, p1772e005, and p2131e002. In some embodiments, the cocktail further comprises p1194. In some embodiments, the cocktail further comprises p1695. In some embodiments, the cocktail further comprises p4430. In some embodiments, the cocktail includes p1106e003, p1835e002, p1772e005, p2131e002, p1194, and p1695. In some embodiments, the cocktail includes p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695.
[0098] The PAM sequence is found in the target gene adjacent to the region where the spacer sequence binds by being complementary to the region, and specifies the point where base pairing with the spacer nucleotide sequence begins. The exact PAM sequence required varies between different CRISPR-Cas systems and is identified through established bioinformatics and experimental procedures. Non-limiting examples of PAMs include CCA, CCT, CCG, TTC, AAG, AGG, ATG, GAG, and / or CC. In Type I systems, the PAM is located immediately 5' to the sequence that matches the spacer, and is 3' to the sequence that base pairs with the spacer nucleotide sequence, allowing it to be directly recognized by the Cascade. Once the protospacer is recognized, the Cascade as a whole recruits the endonuclease Cas3, thereby cleaving and degrading the target DNA. In Type II systems, the PAM is required for Cas9 / sgRNA to form an R-loop to interrogate a specific DNA sequence via Watson-Crick pairing of its guide RNA with the genome. The specificity of the PAM depends on the DNA binding specificity of the Cas9 protein (e.g., the protospacer adjacent to the motif recognition domain at the C-terminus of Cas9).
[0099] In some embodiments, the target nucleotide sequence in the bacteria to be killed is an essential target nucleotide sequence of interest. In some embodiments, the target nucleotide sequence is a non-essential sequence. In some embodiments, the target nucleotide sequence comprises, consists essentially of, or consists of all or a portion of a nucleotide sequence encoding a promoter of an essential gene or its complement. In some embodiments, the spacer nucleotide sequence is complementary to a promoter of an essential gene or a portion thereof. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located on the coding or non-coding strand of an essential gene. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located in the coding of a transcribed region of an essential gene.
[0100] In some embodiments, an essential gene is any gene of an organism that is important for its survival. However, essentiality can vary greatly depending on the environment in which the organism lives. For example, if starch is the only energy source, only genes necessary for starch digestion are essential. In some embodiments, the target nucleotide sequence comprises all or a portion of the promoter sequence for the target gene. In some embodiments, the target nucleotide sequence comprises all or a portion of a nucleotide sequence located in the coding strand of the transcribed region of the target gene. In some embodiments, the target nucleotide sequence comprises at least a portion of an essential gene required for survival of Pseudomonas species. In some embodiments, the target nucleotide sequence comprises a highly conserved non-coding or intergenic sequence. In some embodiments, the target sequence is an intergenic sequence located between the essential gene rpmF and a conserved hypothetical protein. In some embodiments, the essential gene is Tsf, acpP, gapA, infA, secY, csrA, trmD, ftsA, fusA, glyQ, eno, nusG, dnaA, dnaS, pheS, rplB, gltX, hisS, rplC, aspS, gyrB, glnS, dnaE, rpoA, rpoB, pheT, infB, rpsC, rplF, alaS, leuS, serS, rplD, gyrA, glmS, fus, adk, rpsK, rplR, ctrA, parC, tRNA-Ser, tRNA-Asn, or metK. In some embodiments, the essential gene is dnaA, ftsA, gyrB, dnaN, glnS, or rpoB. In some embodiments, the target sequence is PA4325 (hypothetical protein), PA1310 (phnW, pyruvate aminotransferase), or the boundary between PA2970 (rpmF, 50S ribosomal protein L32) and PA2971 (conserved hypothetical protein). In some embodiments, a nonessential gene is any gene in an organism that is not important for its survival. However, being nonessential can be highly dependent on the environment in which the organism lives.
[0101] In some embodiments, non-limiting examples of target nucleotide sequences of interest include target nucleotide sequences encoding transcription factors, translation regulators, polymerase genes, metabolic enzymes, transporters, RNases, proteases, DNA replication enzymes, DNA modification or degradation enzymes, regulatory RNAs, transfer RNAs, or ribosomal RNAs. In some embodiments, the target nucleotide sequences are sequences from genes involved in cell division, cell structure, metabolism, motility, pathogenesis, virulence, or antibiotic resistance. In some embodiments, the target nucleotide sequences are sequences from hypothetical genes whose functions have not yet been characterized. Thus, for example, these genes can be any gene from any bacterium.
[0102] In some embodiments, suitable spacer sequences for the complete construct phage are identified by locating a search set of representative genomes, searching the genomes using relevant parameters, and determining the quality of the spacers for use in the CRISPR-engineered phage.
[0103] First, a suitable search set of representative genomes is located and acquired for the organism / species / target of interest. In some embodiments, the set of representative genomes is found in various databases, including but not limited to, the NCBI GenBank or PATRIC database. NCBI GenBank is one of the largest databases available, containing a mixture of reference genomes and submitted genomes for nearly every organism currently sequenced. Specifically, for pathogenic prokaryotes, the PATRIC (Pathosystems Resource Integration Center) database provides an additional and comprehensive resource of genomes, focusing on clinically relevant strains and genomes related to drug products. Both of the above databases allow bulk downloading of genomes via FTP (File Transfer Protocol) servers, allowing for rapid and programmatic acquisition of datasets.
[0104] The genome is then searched using relevant parameters to locate suitable spacer sequences. In some embodiments, the genome is read from start to finish in both forward and reverse complementary orientations to locate contiguous stretches of DNA containing PAM (protospacer adjacent motif) sites. The spacer sequence is a DNA sequence 3' or 5' (depending on the type of CRISPR system) of length N adjacent to the PAM site, where N is specific to the Cas system of interest and is known globally in advance. Characterization of PAM and spacer sequences is performed, in some embodiments, during Cas system discovery and early research. In some embodiments, all observed PAM-adjacent spacers are saved in a file and / or database for downstream use. The exact PAM sequence required varies between different CRISPR-Cas systems and is identified through established bioinformatics and experimental procedures.
[0105] Next, the quality of the spacers for use in CRISPR-engineered phages is determined. In some embodiments, each observed spacer is evaluated to determine how many evaluated genomes the spacer is present in. In some embodiments, the observed spacers are evaluated to ascertain how frequently they may occur in each given genome. In some embodiments, spacers occurring at more than one location per genome are advantageous because mutations may prevent the Cas system from recognizing the target site, and each additional "backup" site increases the likelihood that a suitable, unmutated target location exists. In some embodiments, the observed spacers are evaluated to determine whether they occur in functionally annotated regions of the genome. If such information is available, functional annotations may be further evaluated to determine whether those genomic regions are "essential" for the survival and function of the organism. By focusing on spacers that occur in all or nearly all (99% or more) of the evaluated genomes of interest, spacer selection may be broadly applicable to many targeted genomes. When there is a large selection pool of conserved spacers, spacers that occur in regions of the genome with known functions may be prioritized, and even more so if those genomic regions are "essential" for survival and occur more than once per genome.
[0106] In some embodiments, the spacer sequence of the complete construct phage is verified. In some embodiments, the first step involves identifying a plasmid that replicates in the organism, species, or target of interest. In some embodiments, the plasmid has a selectable marker. In some embodiments, the selectable marker is an antibiotic resistance gene. In some embodiments, the expression cassette includes the nucleotide sequence of the selectable marker. In some embodiments, the selectable marker is adenine deaminase (ada), blasticidin S deaminase (Bsr, BSD), bleomycin-binding protein (Ble), neomycin phosphotransferase (neo), histidinol dehydrogenase (hisD), glutamine synthetase (GS), dihydrofolate reductase (dhfr), cytosine deaminase (codA), puromycin N-acetyltransferase (Pac), or hygromycin B phosphotransferase (Hph), ampicillin, chloramphenicol, kanamycin, tetracycline, polymyxin B, erythromycin, carbenicillin, streptomycin, spectinomycin, puromycin N-acetyltransferase (Pac), or zeocin (Sh bla). In some embodiments, the selectable marker is a gene involved in thymidylate synthase, thymidine kinase, dihydrofolate reductase, or glutamine synthetase, hi some embodiments, the selectable marker is a gene encoding a fluorescent protein.
[0107] In some embodiments, the second step involves inserting a gene encoding the Cas system into a plasmid to be expressed in the organism, species, or target of interest. In some embodiments, a promoter is provided upstream of the Cas system. In some embodiments, the promoter is recognized by the organism, species, or target of interest to drive expression of the Cas system. Exemplary promoters include the L-arabinose inducible (araBAD, PBAD) promoter, any lac promoter, the L-rhamnose inducible (rhaPBAD) promoter, the T7 RNA polymerase promoter, the trc promoter, the tac promoter, the lambda phage promoter (pLpL-9G-50), the anhydrotetracycline-inducible (tetA) promoter, trp, Ipp, phoA, recA, proU, cst-1, cadA, nar, Ipp-lac, cspA, the 11-lac operator, the T3-lac operator, the T4 gene 32, the T5-lac operator, the nprM-lac operator, Vhb, protein A, the corynebacterium E. coli-like promoter, thr, horn, the diphtheria toxin promoter, sig A, sig Examples of promoters include, but are not limited to, B, nusG, SoxS, katb, α-amylase (Pamy), Ptms, P43 (composed of two overlapping RNA polymerase σ factor recognition sites, σA and σB), Ptms, P43, rplK-rplA, ferredoxin promoter, and / or xylose promoter. In some embodiments, the promoter is BBa_J23102, BBa_J23104, or BBa_J23109. In some embodiments, the promoter is derived from an organism, species, or target bacterium, such as an endogenous CRISPR promoter, an endogenous Cas operon promoter, p16, plpp, or ptat. In some embodiments, the promoter is a phage promoter, such as the promoter for gp105 or gp245. In some embodiments, a ribosome binding site (RBS) is provided between the promoter and the Cas system. In some embodiments, the RBS is recognized by an organism, species, or target of interest.
[0108] In some embodiments, the third step involves providing a genome-targeting spacer into the plasmid. In some embodiments, the genome-targeting spacer is identified using bioinformatics. In some embodiments, the genome-targeting spacer is provided upstream of the repeat-spacer-repeat. In some embodiments, a promoter is provided. In some embodiments, the promoter is recognized by the organism, species, or target of interest to drive expression of the crRNA. In some embodiments, cloning in the third step involves using an organism or species that is not targeted by cloning the spacer.
[0109] In some embodiments, the fourth step comprises providing a non-target spacer to the plasmid expressing the Cas system. In some embodiments, the non-target spacer comprises a sequence that is random. In some embodiments, the non-target spacer comprises a sequence that does not contain a targeting site in the genome of the organism, species, or target of interest. In some embodiments, the non-target spacer sequence is determined using bioinformatics to not contain a targeting site in the genome of the organism, species, or target of interest. In some embodiments, the non-target spacer sequence is provided upstream of the repeat-spacer-repeat. In some embodiments, a promoter is provided. In some embodiments, the promoter is recognized by the organism, species, or target of interest to drive expression of the crRNA.
[0110] In some embodiments, the fifth step comprises determining the effectiveness of each generated spacer. In some embodiments, killing effectiveness is determined. In some embodiments, the effectiveness of each spacer in targeting the bacterial genome is determined. In some embodiments, the plasmid containing the spacer comprises a reduction in migration rate of about 0.5-fold, about 1-fold, 5-fold, 10-fold, 20-fold, 40-fold, 60-fold, 80-fold, or up to about 100-fold compared to a plasmid containing a non-targeting spacer.
[0111] Repetitive nucleotide sequences In some embodiments, the repetitive nucleotide sequences of the CRISPR array comprise the nucleotide sequences of all known repetitive nucleotide sequences of a CRISPR-Cas system. In some embodiments, the repetitive nucleotide sequences are synthetic sequences comprising the secondary structure of a native repeat (e.g., an internal hairpin) from a CRISPR-Cas system. In some embodiments, the repetitive nucleotide sequences differ from each other based on known repetitive nucleotide sequences of a CRISPR-Cas system. In some embodiments, the repetitive nucleotide sequences are each composed of a distinct secondary structure of a native repeat (e.g., an internal hairpin) from a CRISPR-Cas system. In some embodiments, the repetitive nucleotide sequences are a combination of distinct repetitive nucleotide sequences operable in a CRISPR-Cas system.
[0112] In some embodiments, the spacer sequence is attached at its 5' end to the 3' end of the repeat sequence. In some embodiments, the spacer sequence is attached at its 5' end about 1 to about 8, about 1 to about 10, or about 1 to about 15 nucleotides from the 3' end of the repeat sequence. In some embodiments, about 1 to about 8, about 1 to about 10, or about 1 to about 15 nucleotides of the repeat sequence are part of the 3' end of the repeat sequence. In some embodiments, the spacer nucleotide sequence is attached at its 3' end to the 5' end of the repeat sequence. In some embodiments, the spacer is attached at its 3' end about 1 to about 8, about 1 to about 10, or about 1 to about 15 nucleotides from the 5' end of the repeat sequence. In some embodiments, about 1 to about 8, about 1 to about 10, or about 1 to about 15 nucleotides of the repeat sequence are part of the 5' end of the repeat sequence.
[0113] In some embodiments, a spacer nucleotide sequence is attached at its 5' end to a first repeat sequence and at its 3' end to a second repeat sequence to form a repeat-spacer-repeat sequence. In some embodiments, the spacer sequence is attached at its 5' end to the 3' end of the first repeat sequence and at its 3' end to the 5' end of the second repeat sequence, and the spacer sequence and second repeat sequence are repeated to form a repeat-(spacer-repeat)n sequence, where n is an integer between 1 and 100. In some embodiments, the sequence of Repeat-(spacer-repeat)n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 , 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more spacer nucleotide sequences.
[0114] In some embodiments, the repeat sequence is identical or substantially identical to a repeat sequence from a wild-type CRISPR locus. In some embodiments, the repeat sequence is a repeat sequence found in Table 3. In some embodiments, the repeat sequence is a sequence described herein. In some embodiments, the repeat sequence comprises a portion of the wild-type repeat sequence (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more contiguous nucleotides of the wild-type repeat sequence). In some embodiments, the repeat sequence comprises, consists essentially of, or consists of at least one nucleotide (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more nucleotides, or any range therein). In some embodiments, the repeat sequence comprises, consists essentially of, or consists of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 or less nucleotides. In some embodiments, the repeat sequence comprises about 20-40, 21-40, 22-40, 23-40, 24-40, 25-40, 26-40, 27-40, 28-40, 29-40, 30-30, 31-40, 32-40, 33-40, 34-40, 35-40, 36-40, 37-40, 38-40, 39-40, 20-39, 20-38, 20-37, 20-36, 20-35, 20-34, 20-33, 20-32, 20-31, 20-30, 20-29, 20-28, 20-26, 20-25, 20-24, 20-23, 20-22, or 20-21 nucleotides.In some embodiments, the repeat sequence comprises about 20-35, 21-35, 22-35, 23-35, 24-35, 25-35, 26-35, 27-35, 28-35, 29-35, 30-30, 31-35, 32-35, 33-35, 34-35, 25-40, 25-39, 25-38, 25-37, 25-36, 25-35, 25-34, 25-33, 25-32, 25-31, 25-30, 25-29, 25-28, or 25-26 nucleotides. In some embodiments, the system is a Pseudomonas aeruginosa Type IC Cas system. In some embodiments, the Pseudomonas aeruginosa Type IC Cas system has a repeat length of about 25-38 nucleotides.
[0115] In some embodiments, the repeat sequence comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 26-30. In some examples, the repeat sequence comprises at least or about 95% homology to any one of SEQ ID NOs: 26-30. In some examples, the repeat sequence comprises at least or about 97% homology to any one of SEQ ID NOs: 26-30. In some examples, the repeat sequence comprises at least or about 99% homology to any one of SEQ ID NOs: 26-30. In some examples, the repeat sequence comprises 100% homology to any one of SEQ ID NOs: 26-30. In some examples, the repeat sequence comprises at least a portion having at least or about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or more than 32 nucleotides of any one of SEQ ID NOs: 26-30. In some embodiments, the repeat is engineered into a PhiKZ virus. In some embodiments, the PhiKZ virus is p1194 or p4430. In some embodiments, the repeat is engineered into a PhiKMV virus. In some embodiments, the PhiKMV virus is p2167. In some embodiments, the repeat is engineered into a Brunyoghe virus. In some embodiments, the Brunyoghe virus is p1695 or p3278. In some embodiments, the repeat is engineered into a Samuna virus. In some embodiments, the Samuna virus is p1772, p2131, p2132, or p2973. In some embodiments, repeats are engineered into a Pbuna virus. In some embodiments, the Pbuna virus is p1106, p1587, p1835, p2037, p2363, p2421, or pb1. In some embodiments, repeats are engineered into a Nankoku virus. In some embodiments, repeats are engineered into an Abidjan virus.In some embodiments, a CRISPR array is engineered into a Baikal virus. In some embodiments, repeats are engineered into a Beetre virus. In some embodiments, repeats are engineered into a Casadaban virus. In some embodiments, repeats are engineered into a Citex virus. In some embodiments, a CRISPR array is engineered into a Cysto virus. In some embodiments, repeats are engineered into a Detre virus. In some embodiments, repeats are engineered into an El virus. In some embodiments, a CRISPR array is engineered into a Holloway virus. In some embodiments, repeats are engineered into a Kochitakasu virus. In some embodiments, repeats are engineered into a Lituna virus. In some embodiments, repeats are engineered into a Luzseptima virus. In some embodiments, repeats are engineered into a Nipuna virus. In some embodiments, repeats are engineered into a Pakpuna virus. In some embodiments, repeats are engineered into a Pamex virus. In some embodiments, repeats are engineered into a Paundecim virus. In some embodiments, the repeats are engineered into a Phitre virus. In some embodiments, the repeats are engineered into a Primolici virus. In some embodiments, the repeats are engineered into a Septimtre virus. In some embodiments, the repeats are engineered into a Stubbur virus. In some embodiments, the repeats are engineered into a Tertilici virus. In some embodiments, the repeats are engineered into a Yua virus. In some embodiments, the repeats are engineered into a Zicotria virus. In some embodiments, the repeats are part of a CRISPR array engineered into a bacteriophage.
[0116] Type I CRISPR-Cas system In some embodiments, the type I CRISPR-Cas system is a type IA system, a type IB system, a type IC system, a type ID system, a type IE system, or a type IF system. In some embodiments, the type I CRISPR-Cas system is a type IA system. In some embodiments, the type I CRISPR-Cas system is a type IB system. In some embodiments, the type I CRISPR-Cas system is a type IC system. In some embodiments, the type I CRISPR-Cas system is a type ID system. In some embodiments, the type I CRISPR-Cas system is a type IE system. In some embodiments, the type I CRISPR-Cas system is an IF system. In some embodiments, the type I CRISPR-Cas system comprises a cascade polypeptide. The type I cascade polypeptide processes the CRISPR array to produce processed RNA that is then used to bind complexes to target sequences complementary to the spacer in the processed RNA. In some embodiments, the type I cascade complex is a type IA cascade polypeptide, a type IB cascade polypeptide, a type IC cascade polypeptide, a type ID cascade polypeptide, a type IE cascade polypeptide, a type IF cascade polypeptide, or a type I-∪ cascade polypeptide.
[0117] In some embodiments, a type I Cascade complex comprises: (a) a nucleotide sequence encoding a Cas7 (Csa2) polypeptide, a nucleotide sequence encoding a Cas8a1 (Csx13) polypeptide or a Cas8a2 (Csx9) polypeptide, a nucleotide sequence encoding a Cas5 polypeptide, a nucleotide sequence encoding a Csa5 polypeptide, a nucleotide sequence encoding a Cas6a polypeptide, a nucleotide sequence encoding a Cas3′ polypeptide, and a nucleotide sequence encoding a Cas3″ having no nuclease activity (type IA); (b) a nucleotide sequence encoding a Cas6b polypeptide, a nucleotide sequence encoding a Cas8b (Csh1) polypeptide, a nucleotide sequence encoding a Cas7 (Csh2) polypeptide, and a nucleotide sequence encoding a Cas5 polypeptide (type IB); (c) a nucleotide sequence encoding a Cas5d polypeptide, a nucleotide sequence encoding a Cas8c (Csd1) polypeptide, and a nucleotide sequence encoding a Cas7 (Csd2) polypeptide (type IC); (d) a nucleotide sequence encoding a Cas5d polypeptide, a nucleotide sequence encoding a Cas8c (Csd1) polypeptide, and a nucleotide sequence encoding a Cas7 (Csd2) polypeptide (type IC); (e) a nucleotide sequence encoding a Cse1 (CasA) polypeptide, a nucleotide sequence encoding a Cse2 (CasB) polypeptide, a nucleotide sequence encoding a Cas7 (CasC) polypeptide, a nucleotide sequence encoding a Cas5 (CasD) polypeptide, and a nucleotide sequence encoding a Cas6e (CasE) polypeptide (IE type); and / or (f) a nucleotide sequence encoding a Cys1 polypeptide, a nucleotide sequence encoding a Cys2 polypeptide, a nucleotide sequence encoding a Cas7 (Cys3) polypeptide, and a nucleotide sequence encoding a Cas6f) polypeptide (IF type).
[0118] In some embodiments, the type I CRISPR-Cas system is exogenous to the target bacterium. In some embodiments, the exogenous type I CRISPR-Cas system comprises: (a) a nucleotide sequence encoding a Cas7 (Csa2) polypeptide, a nucleotide sequence encoding a Cas8a1 (Csx13) polypeptide or a Cas8a2 (Csx9) polypeptide, a nucleotide sequence encoding a Cas5 polypeptide, a nucleotide sequence encoding a Csa5 polypeptide, a nucleotide sequence encoding a Cas6a polypeptide, a nucleotide sequence encoding a Cas3' polypeptide, and a nucleotide sequence encoding a Cas3" that does not have nuclease activity (Type IA); (b) a nucleotide sequence encoding a Cas6b polypeptide, a nucleotide sequence encoding a Cas8b (Csh1) polypeptide, a nucleotide sequence encoding a Cas7 (Csh2) polypeptide, and a nucleotide sequence encoding a Cas5 polypeptide (Type IB); (c) a nucleotide sequence encoding a Cas5d polypeptide, a nucleotide sequence encoding a Cas8c (Csd1) polypeptide, and a nucleotide sequence encoding a Cas7 (Csd2) polypeptide (Type IC); (d) a nucleotide sequence encoding a Cas6b polypeptide, a nucleotide sequence encoding a Cas8b (Csh1) polypeptide, a nucleotide sequence encoding a Cas7 (Csd2) polypeptide, and a nucleotide sequence encoding a Cas5 polypeptide (Type IC); (e) a nucleotide sequence encoding a Cse1 (CasA) polypeptide, a nucleotide sequence encoding a Cse2 (CasB) polypeptide, a nucleotide sequence encoding a Cas7 (CasC) polypeptide, a nucleotide sequence encoding a Cas5 (CasD) polypeptide, and a nucleotide sequence encoding a Cas6e (CasE) polypeptide (IE type); and / or (f) a nucleotide sequence encoding a Cys1 polypeptide, a nucleotide sequence encoding a Cys2 polypeptide, a nucleotide sequence encoding a Cas7 (Cys3) polypeptide, and a nucleotide sequence encoding a Cas6f) polypeptide (IF type).
[0119] In some embodiments, the Type I CRISPR-Cas system exogenous to the target bacterium comprises a nucleotide sequence encoding a Cas5d polypeptide, a nucleotide sequence encoding a Cas8c (Csd1) polypeptide, and a nucleotide sequence encoding a Cas7 (Csd2) polypeptide (Type I C).
[0120] Bacteriophage In some embodiments, the bacteriophage is an obligately lytic bacteriophage. In some embodiments, the bacteriophage is a temperate bacteriophage in which the lysogenic genes have been retained. In some embodiments, the bacteriophage is a temperate bacteriophage in which some lysogenic genes have been removed. In some embodiments, the bacteriophage is a temperate bacteriophage in which one lysogenic gene has been removed, replaced, or inactivated to confer lytic properties.
[0121] In some embodiments, the bacteriophage targets Pseudomonas species. In some embodiments, the bacteriophage targets Pseudomonas aeruginosa. In some embodiments, the bacteriophage specifically targets Pseudomonas species over other bacterial species. In some embodiments, the bacteriophage targets Pseudomonas species in the absence of a CRISPR-Cas system. In some embodiments, the bacteriophage binds to lipopolysaccharide. In some embodiments, the bacteriophage binds to type IV pili. In some embodiments, the bacteriophage binds to the outer membrane porin OprM. In some embodiments, the target refers to a bacteriophage that infects bacteria. In some embodiments, the target refers to a bacteriophage that kills bacteria. In some embodiments, the target specifically refers to a bacteriophage that infects a first bacterial species but not a second bacterial species. In some embodiments, the target specifically refers to a bacteriophage that kills a first bacterial species but not a second bacterial species.
[0122] In some embodiments, the bacteriophage herein is or is engineered from a bacteriophage that infects Pseudomonas. In some embodiments, the bacteriophage that infects Pseudomonas is PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimtre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the bacteriophage that infects Pseudomonas includes a subtype of wild-type Pbuna virus phage listed in Table 5A, which infects the target Pseudomonas as marked with a plus sign (+) (e.g., phage p1106 infects b002548). In some embodiments, the bacteriophage that infects Pseudomonas includes a subtype of engineered Pbuna virus phage listed in Table 5A, which infects the target Pseudomonas as marked with a plus sign (+) (e.g., p1106e003 infects b002548).In some embodiments, the bacteriophage that infects the Pseudomonas includes a wild-type Samuna virus phage subtype, an engineered Samuna virus phage subtype, a wild-type PhiKZ virus, a wild-type PhiKMV virus, or a wild-type Bruynoghe virus, e.g., as listed in Table 5B, which infects the target Pseudomonas as marked with a plus sign (+). As listed in Table 5A, the wild-type Pbuna virus phage subtype can be p1106, p1587, p1835, p2037, p2363, p2421, and / or pb1, while the engineered Pbuna virus phage subtype can be p1106e003, p1587e002, p1835e002, p2037e002, p2363e003, and / or p2421e002. As listed in Table 5B, the phage subtype of wild-type Samuna virus can be p1772, p2131, p2132, and / or p2973; the phage subtype of engineered Samuna virus can be pb1e002, p1772e005, p2131e002, p2132e002, and / or p2973e002; the phage subtype of wild-type PhiKZ virus can be p1194 and / or p4430; the phage subtype of wild-type PhiKMV virus can be p2167; and the phage subtype of wild-type Bruynoghe virus can be p1695 and p3278. In some embodiments, the bacteriophage infecting Pseudomonas is Nankoku virus. In some embodiments, the bacteriophage infecting Pseudomonas is Abidjan virus. In some embodiments, the bacteriophage that infects Pseudomonas is Baikal virus. In some embodiments, the bacteriophage that infects Pseudomonas is Beetre virus. In some embodiments, the bacteriophage that infects Pseudomonas is Casadaba virus. In some embodiments, the bacteriophage that infects Pseudomonas is Citex virus.In some embodiments, the bacteriophage that infects Pseudomonas is a cystovirus. In some embodiments, the bacteriophage that infects Pseudomonas is a Detre virus. In some embodiments, the bacteriophage that infects Pseudomonas is an El virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Holloway virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Kochitakasu virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Lituna virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Luzseptima virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Nipuna virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Pakpuna virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Pamex virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Paundecim virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Phitre virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Primolici virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Septimtre virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Stubbur virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Tertilici virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Yua virus. In some embodiments, the bacteriophage that infects Pseudomonas is a Zicotria virus. In some embodiments, the bacteriophage that infects Pseudomonas kills Pseudomonas.In some embodiments, bacteriophages that infect Pseudomonas do not infect Staphylococcus aureus. In some embodiments, bacteriophages that infect Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not infect Staphylococcus aureus. In some embodiments, bacteriophages that kill Pseudomonas do not kill Staphylococcus aureus. In some embodiments, bacteriophages that infect Pseudomonas do not infect Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not kill Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not infect Klebsiella pneumoniae. In some embodiments, bacteriophages that infect Pseudomonas do not kill Klebsiella pneumoniae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterococcus faecium. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Enterobacter cloacae. In some embodiments, the bacteriophage that kills Pseudomonas does not kill Enterobacter cloacae. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Acinetobacter baumannii.In some embodiments, the bacteriophage that infects Pseudomonas does not infect Acinetobacter baumannii. In some embodiments, the bacteriophage that kills Pseudomonas does not kill Acinetobacter baumannii. In some embodiments, the bacteriophage that infects Pseudomonas does not infect Staphylococcus epidermidis. In some embodiments, the bacteriophage that infects Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the bacteriophage that kills Pseudomonas does not infect Staphylococcus epidermidis. In some embodiments, the bacteriophage that kills Pseudomonas does not kill Staphylococcus epidermidis. In some embodiments, the combination of bacteriophages infects Pseudomonas. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A. As a non-limiting example, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As non-limiting examples, the combination infects at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B. In some embodiments, the bacteriophage combination kills the Pseudomonas. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5A.As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 5B. As non-limiting examples, the combination kills at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the Pseudomonas in Table 6B.
[0123] In some embodiments, the bacteriophage is present in a cocktail that includes other bacteriophages, and each of the bacteriophages does not interfere with the function of the other bacteriophages in the cocktail.
[0124] In some embodiments, the bacteriophage is a PhiKZ virus, a PhiKMV virus, a Brunyoghe virus, a Samuna virus, a Nankoku virus, an Abidjan virus, a Baikal virus, a Beetre virus, a Casadaban virus, a Citex virus, a Cystovirus, a Detre virus, an El virus, a Holloway virus, a Kochitakasu virus, a Lituna virus, a Luzseptima virus, a Nipuna virus, a Pakpuna virus, a Pamex virus, a Paundecim virus, a Phitre virus, a Primolici virus, a Septimatre virus, a Stubbur virus, a Tertilici virus, a Yua virus, a Zicotria virus, or a Pbuna virus. In some embodiments, the bacteriophage is a PhiKZ virus. In some embodiments, the bacteriophage is a PhiKMV virus. In some embodiments, the bacteriophage is a Brunyoghe virus. In some embodiments, the bacteriophage is a Samuna virus. In some embodiments, the bacteriophage is a Pbuna virus. In some embodiments, the bacteriophage comprises a CRISPR-Cas3 system.In some embodiments, the bacteriophage is p1106 (ATCC Deposit No. PTA-127024), p1194 (ATCC Deposit No. PTA-127025), p1587 (ATCC Deposit No. PTA-127027), p1695 (ATCC Deposit No. PTA-127028), p1772 (ATCC Deposit No. PTA-127030), p1835 (ATCC Deposit No. PTA-127032), p2037 (ATCC Deposit No. PTA-127034), p2131 (ATCC Deposit No. PTA-127036), p2132 (ATCC Deposit No. PTA-127038), p2167 (ATCC Deposit No. PTA-127039), p2363 (ATCC Deposit No. PTA-127041), p2421 (ATCC Deposit No. PTA-127043), p2973 (ATCC Deposit No. PTA-127045), p3278 (ATCC Deposit No. PTA-127046), p4430 (ATCC Deposit No. PTA-127047), or PB1 (ATCC Deposit No. PTA-127049), which target Pseudomonas species.
[0125] In some embodiments, the bacteriophage is p1106, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1106. In some embodiments, the bacteriophage is a p1106 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p1106e003 (ATCC deposit number PTA-127023). In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1106e003.
[0126] In some embodiments, the bacteriophage is p1194, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1194. In some embodiments, the bacteriophage is a p1194 bacteriophage that comprises a CRISPR-Cas system.
[0127] In some embodiments, the bacteriophage is p1587, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1587. In some embodiments, the bacteriophage is a p1587 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p1587e002 (ATCC Deposit No. PTA-127026). In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of 01587e002.
[0128] In some embodiments, the bacteriophage is p1695, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1695. In some embodiments, the bacteriophage is a p1695 bacteriophage that comprises a CRISPR-Cas system.
[0129] In some embodiments, the bacteriophage is p1772, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1772. In some embodiments, the bacteriophage is a p1772 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p1772e005 (ATCC Deposit No. PTA-127029). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence of p1772e005.
[0130] In some embodiments, the bacteriophage is p1835, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1835. In some embodiments, the bacteriophage is a p1835 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p1835e002 (ATCC Deposit No. PTA-127026). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1835e002.
[0131] In some embodiments, the bacteriophage is p2037, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2037. In some embodiments, the bacteriophage is a p2037 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2037e002 (ATCC Deposit No. PTA-127033). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2037e002.
[0132] In some embodiments, the bacteriophage is p2131, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2131. In some embodiments, the bacteriophage is a p2131 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2131 (ATCC deposit number PTA-127035). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2131.
[0133] In some embodiments, the bacteriophage is p2132, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2132. In some embodiments, the bacteriophage is a p2132 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2132e002 (ATCC Deposit No. PTA-127037). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2132e002.
[0134] In some embodiments, the bacteriophage is p2167, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2167. In some embodiments, the bacteriophage is a p2167 bacteriophage that comprises a CRISPR-Cas system.
[0135] In some embodiments, the bacteriophage is p2163, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2163. In some embodiments, the bacteriophage is a p2163 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2163e003 (ATCC Deposit No. PTA-127040). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2163e003.
[0136] In some embodiments, the bacteriophage is p2421, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2421. In some embodiments, the bacteriophage is a p2421 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2141e0002 (ATCC Deposit No. PTA-127042). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2141e0002.
[0137] In some embodiments, the bacteriophage is p2973, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2973. In some embodiments, the bacteriophage is a p2973 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is p2973e002 (ATCC deposit number PTA-127044). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2973e002.
[0138] In some embodiments, the bacteriophage is p3278, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p3278. In some embodiments, the bacteriophage is a p3278 bacteriophage that comprises a CRISPR-Cas system.
[0139] In some embodiments, the bacteriophage is p4430, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p4430. In some embodiments, the bacteriophage is a p1106 bacteriophage that comprises a CRISPR-Cas system. In some embodiments, the bacteriophage is PB1, or a variant thereof, that retains the ability to target Pseudomonas species. In some embodiments, the bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to PB1. In some embodiments, the bacteriophage is a PB1 bacteriophage comprising a CRISPR-Cas system. In some embodiments, the bacteriophage is PB1e002 (ATCC deposit number PTA-127049). In some embodiments, the bacteriophage comprises at least 70%, 775%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to PB1e002.
[0140] In some embodiments, the bacteriophage comprises a phage listed in Table 1A, or a variant thereof, that retains the ability to target Pseudomonas species.
[0141] Also disclosed herein are cocktails comprising two or more bacteriophages, in some embodiments, the two or more bacteriophages are selected from the lineage of PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cystovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimatre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the cocktail comprises at least six bacteriophages, wherein the bacteriophages include PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, and Pbuna virus. In some embodiments, the cocktail comprises at least one Pbuna virus, at least one Samuna virus, at least one PhiKZ virus, and at least one Bruynoghe virus. In some embodiments, at least one bacteriophage of the cocktail comprises a CRISPR-Cas system. In some embodiments, at least two bacteriophages of the cocktail comprise a CRISPR-Cas system. In some embodiments, at least three bacteriophages of the cocktail comprise a CRISPR-Cas system. In some embodiments, at least four bacteriophages of the cocktail comprise a CRISPR-Cas system. In some embodiments, at least one bacteriophage of the cocktail does not comprise a CRISPR-Cas system. In some embodiments, at least two bacteriophages of the cocktail do not comprise a CRISPR-Cas system.
[0142] In some embodiments, the cocktail comprises at least two bacteriophages, the bacteriophages comprising p1106, p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1, or two or more phages thereof. In some embodiments, the cocktail comprises a first bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1106e003. In some embodiments, the cocktail includes a second bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1835e002. In some embodiments, the cocktail includes a third bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1772e005. In some embodiments, the cocktail includes a fourth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2131e002. In some embodiments, the cocktail includes a fifth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194. In some embodiments, the cocktail includes a fifth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p4430. In some embodiments, the cocktail includes a fifth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1695.In some embodiments, the cocktail comprises a sixth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p4430. In some embodiments, the cocktail comprises a sixth bacteriophage that comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1695.
[0143] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1106. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0144] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1106. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1106, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1106, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1106, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1106, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1106, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0145] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1587. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1106, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1106, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1106, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1106, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1106, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0146] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1695. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1106, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1106, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1106, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1106, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1106, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0147] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1772. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1106, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1106, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1106, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1106, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1106, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0148] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1835. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1106, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1106, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1106, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1106, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1106, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0149] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2037. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p1106, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p1106, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p1106, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p1106, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p1106, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0150] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2131. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p1106, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p1106, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p1106, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p1106, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p1106, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0151] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2132. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p1106, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p1106, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p1106, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p1106, p2167, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p1106, p2167, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0152] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2167. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p1106, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p1106, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p1106, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p1106, p2363, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p1106, p2363, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0153] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2363. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p1106, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p1106, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p1106, p2421, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p1106, p2421, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p1106, p2421, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0154] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2421. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p1106, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p1106, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p1106, p2973, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p1106, p2973, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, and the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p1106, p2973, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0155] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p2973. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p1106, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p1106, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p1106, p3278, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p1106, p3278, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p1106, p3278, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0156] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p3278. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p1106, p4430, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p1106, p4430, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p1106, p4430, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p1106, p4430, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p1106, p4430, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0157] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p4430. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p1106, or PB1. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p1106, or PB1. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p1106, or PB1. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p1106, or PB1.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p1106, or PB1. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0158] In some embodiments, the first bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to PB1. In some embodiments, the cocktail comprises a second bacteriophage, and the second bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or p1106. In some embodiments, the cocktail comprises a third bacteriophage, wherein the third bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or p1106. In some embodiments, the cocktail comprises a fourth bacteriophage, wherein the fourth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or p1106. In some embodiments, the cocktail comprises a fifth bacteriophage, wherein the fifth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or p1106.In some embodiments, the cocktail includes a sixth bacteriophage, wherein the sixth bacteriophage comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of p1194, p1587, p1695, p1772, p1835, p2037, p2131, p2132, p2167, p2363, p2421, p2973, p3278, p4430, or p1106. In some embodiments, at least one, two, three, or four bacteriophages comprise a CRISPR-Cas system. In some embodiments, at least one or two bacteriophages do not comprise a CRISPR-Cas system.
[0159] In some embodiments, the bacteriophage of interest is obtained from an environmental source or a market research supplier. In some embodiments, the obtained bacteriophage is screened against a library of bacteria and its related strains for lytic activity. In some embodiments, the bacteriophage is screened against a library of bacteria and its related strains for the ability to generate primary resistance in the screened bacteria.
[0160] Pseudomonas species In some embodiments, the bacterium is Pseudomonas, hi some embodiments, the bacterium is Pseudomonas aeruginosa.
[0161] In some embodiments, Pseudomonas species cause, contribute to, and / or cause complications of an infection, disease, or condition, and the compositions and methods described herein are used to treat the infection, disease, or condition. In some embodiments, the infection, disease, or condition is acute or chronic. In some embodiments, the infection, disease, or condition is localized or systemic. In some embodiments, the infection, disease, or condition is idiopathic. In some embodiments, the infection, disease, or condition is acquired by means including, but not limited to, respiratory inhalation, ingestion, skin and wound infections, blood circulation infections, middle ear infections, gastrointestinal tract infections, peritoneal infections, urinary tract infections, genitourinary tract infections, oral soft tissue infections, intraperitoneal infections, epidermal or mucosal absorption, eye infections (including contact lens contamination), endocarditis, infections in cystic fibrosis, infections of indwelling medical devices such as artificial joints, dental implants, catheters, and cardiac implants, sexual contact, and / or hospital-acquired infections and ventilator-associated bacterial pneumonia. In some embodiments, Pseudomonas species cause urinary tract infections. In some embodiments, Pseudomonas species cause and / or exacerbate inflammatory bowel disease. In some embodiments, Pseudomonas species cause and / or exacerbate autoimmune diseases. In some embodiments, Pseudomonas species cause and / or exacerbate inflammatory bowel disease (IBD). In some embodiments, Pseudomonas species cause and / or exacerbate psoriasis. In some embodiments, Pseudomonas species cause and / or exacerbate psoriatic arthritis (PA). In some embodiments, Pseudomonas species cause and / or exacerbate rheumatoid arthritis (RA). In some embodiments, Pseudomonas species cause and / or exacerbate systemic lupus erythematosus (SLE). In some embodiments, Pseudomonas species cause and / or exacerbate multiple sclerosis (MS). In some embodiments, Pseudomonas species cause and / or exacerbate Graves' disease. In some embodiments, Pseudomonas species cause and / or exacerbate Hashimoto's thyroiditis.In some embodiments, Pseudomonas species cause and / or exacerbate myasthenia gravis. In some embodiments, Pseudomonas species cause and / or exacerbate vasculitis. In some embodiments, Pseudomonas species cause and / or exacerbate cancer. In some embodiments, Pseudomonas species cause and / or exacerbate cancer progression. In some embodiments, Pseudomonas species cause and / or exacerbate cancer metastasis. In some embodiments, Pseudomonas species cause and / or exacerbate resistance to cancer treatment. In some embodiments, treatments used to address cancer include, but are not limited to, chemotherapy, immunotherapy, hormone therapy, targeted drug therapy, and / or radiation therapy. In some embodiments, the cancer develops in organs including, but not limited to, the anus, bladder, blood and blood components, bone, bone marrow, brain, breast, cervix, colon and rectum, esophagus, kidney, larynx, lymphatic system, muscle (i.e., soft tissue), oral cavity and pharynx, ovaries, pancreas, prostate, skin, small intestine, stomach, testicles, thyroid, uterus, and / or vulva. In some embodiments, Pseudomonas species cause and / or exacerbate central nervous system (CNS) disorders. In some embodiments, Pseudomonas species cause and / or exacerbate attention deficit hyperactivity disorder (ADHD). In some embodiments, Pseudomonas species cause and / or exacerbate vasculitis. In some embodiments, Pseudomonas species cause and / or exacerbate bipolar disorder. In some embodiments, Pseudomonas species cause and / or exacerbate major depressive disorder. In some embodiments, Pseudomonas species cause and / or exacerbate epilepsy. In some embodiments, Pseudomonas species cause and / or exacerbate neurodegenerative disorders, including, but not limited to, Alzheimer's disease, Huntington's disease, and / or Parkinson's disease.In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat any one of the diseases, disorders, or symptoms associated with the aforementioned diseases or disorders. In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used in combination with one or more other drugs for the treatment or alleviation of one or more symptoms associated with the disease to treat the aforementioned diseases, disorders, or symptoms associated with the aforementioned diseases or disorders.
[0162] Cystic fibrosis and cystic fibrosis-associated bronchiectasis are associated with infections caused by Pseudomonas aeruginosa. See, for example, P. Farrell et al., Radiology, Vol. 252, No. 2, pp. 534-543 (2009). In some embodiments, one or more bacteriophages are administered to patients with cystic fibrosis or cystic fibrosis-associated bronchiectasis. In some embodiments, a combination of two or more bacteriophages is administered to patients with cystic fibrosis or cystic fibrosis-associated bronchiectasis. In some embodiments, administering a bacteriophage to a patient with cystic fibrosis or cystic fibrosis-associated bronchiectasis reduces the bacterial load in the patient. In some embodiments, the reduction in bacterial load results in clinical improvement in patients with cystic fibrosis or cystic fibrosis-associated bronchiectasis.
[0163] Non-cystic fibrosis bronchiectasis is associated with infection with Pseudomonas aeruginosa. See, for example, R. Wilson et al., "Respiratory Medicine, Vol. 117," pp. 179-189 (2016). In some embodiments, one or more bacteriophages are administered to patients with non-cystic fibrosis bronchiectasis. In some embodiments, a combination of two or more bacteriophages is administered to patients with non-cystic fibrosis bronchiectasis. In some embodiments, administering a bacteriophage to a patient with non-cystic fibrosis bronchiectasis reduces the bacterial load in the patient. In some embodiments, the reduction in bacterial load results in clinical improvement in patients with non-cystic fibrosis bronchiectasis.
[0164] In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is administered to a subject having an infection with P. aeruginosa or a disease caused directly or indirectly by P. aeruginosa. In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat bloodstream infections caused by P. aeruginosa. In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is suitable for treating respiratory inhalation, ingestion, skin, and wound infections caused by P. aeruginosa. In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat circulatory infections, middle ear infections, gastrointestinal infections, peritoneal infections, urinary tract infections, genitourinary tract infections, oral soft tissue infections, intraperitoneal infections, epidermal or mucosal absorption, eye infections (including contact lens contamination), urinary tract infections, endocarditis, infections in cystic fibrosis, infections of indwelling medical devices such as artificial joints, dental implants, catheters, and cardiac implants, sexual contact, and / or hospital-acquired infections and ventilator-associated bacterial pneumonia associated with infections by Pseudomonas aeruginosa. In some embodiments, Pseudomonas species cause and / or exacerbate inflammatory diseases, and a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat inflammatory diseases. In some embodiments, Pseudomonas species cause and / or exacerbate an autoimmune disease, and a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat the autoimmune disease.In some embodiments, Pseudomonas species cause and / or exacerbate inflammatory bowel disease (IBD), and compositions disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, are used to treat IBD. In some embodiments, the bacteriophage is selected from Table 1A, Table 5A, and / or Table 5B. In some embodiments, compositions disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, are used to treat disease and reduce bacterial load. In some embodiments, compositions disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, are used to treat disease and reduce inflammation. In some embodiments, the compositions disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, are used to treat disease and reduce one or more symptoms associated with a bacterial infection or one or more sequelae of a bacterial infection.
[0165] In some embodiments, the treatment is administered as an intravenous or intramuscular drug. In some embodiments, the treatment is administered via the oral route. In some embodiments, the treatment is administered via a nebulizer. In some embodiments, the treatment is administered via a patient-operable nebulizer. In some embodiments, the treatment is administered via a metered-dose nebulizer. In some embodiments, the treatment is administered in combination with one or more other drugs or therapies.
[0166] In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat cancer. In some embodiments, the bacteriophage is selected from Table 1A, Table 5A, and / or Table 5B.
[0167] In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat pneumonia. In some embodiments, the bacteriophage is selected from Table 1A, Table 5A, and / or Table 5B.
[0168] In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat cystic fibrosis bronchiectasis. In some embodiments, administering the bacteriophage to a patient with cystic fibrosis or bronchiectasis associated with cystic fibrosis reduces the bacterial load in the patient. In some embodiments, the reduction in bacterial load results in clinical improvement in the patient with cystic fibrosis bronchiectasis. In some embodiments, the bacteriophage is selected from Table 1A, Table 5A, and / or Table 5B. In some embodiments, the treatment is administered as an intravenous or intramuscular drug. In some embodiments, the treatment is administered via the oral route. In some embodiments, the treatment is administered via a nebulizer. In some embodiments, the treatment is administered via a nebulizer operable by the patient. In some embodiments, the treatment is administered via a metered-dose nebulizer. In some embodiments, the treatment is administered in combination with one or more other drugs or therapies.
[0169] In some embodiments, a composition disclosed herein, such as one or more bacteriophages, engineered bacteriophages, or bacteriophage cocktails described herein, is used to treat non-cystic fibrosis bronchiectasis. In some embodiments, administering the bacteriophage to a patient with non-cystic fibrosis bronchiectasis or fibrosis-associated bronchiectasis reduces the bacterial load in the patient. In some embodiments, the reduction in bacterial load results in clinical improvement in patients with non-cystic fibrosis bronchiectasis or fibrosis-associated bronchiectasis. In some embodiments, the bacteriophage is selected from Table 1A, Table 5A, and / or Table 5B. In some embodiments, the treatment is administered as an intravenous or intramuscular drug. In some embodiments, the treatment is administered via the oral route. In some embodiments, the treatment is administered via a nebulizer. In some embodiments, the treatment is administered via a nebulizer operable by the patient. In some embodiments, the treatment is administered via a metered-dose nebulizer. In some embodiments, the treatment is administered in combination with one or more other drugs or therapies.
[0170] In some embodiments, the treatment comprises a composition, e.g., a pharmaceutical composition, comprising one or more bacteriophages, e.g., a bacteriophage cocktail, wherein the bacteriophages, e.g., a bacteriophage cocktail, in the composition are from a lineage consisting of PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Schistovirus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimtre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus. In some embodiments, the composition comprises a bacteriophage cocktail 511. In some embodiments, the composition comprises bacteriophage cocktail PACK 512. Provided herein in some embodiments is a pharmaceutical composition comprising at least six bacteriophages, wherein the bacteriophages are from the group consisting of p1106e003, p1835e002, p1772e005, p2131e002, p4430, and p1695.
[0171] Insertion site In some embodiments, insertion of a nucleic acid sequence into a bacteriophage preserves the lytic activity of the bacteriophage. In some embodiments, the nucleic acid sequence is inserted into the bacteriophage genome. In some embodiments, the nucleic acid sequence is inserted into the bacteriophage genome at a transcription terminator site at the end of an operon of interest. In some embodiments, the nucleic acid sequence is inserted into the bacteriophage genome in place of one or more removed non-essential genes. In some embodiments, the nucleic acid sequence is inserted into the bacteriophage genome in place of one or more removed lysogenic genes. In some embodiments, replacement of non-essential and / or lysogenic genes with the nucleic acid sequence does not affect the lytic activity of the bacteriophage. In some embodiments, replacement of non-essential and / or lysogenic genes with the nucleic acid sequence preserves the lytic activity of the bacteriophage. In some embodiments, replacement of non-essential and / or lysogenic genes with the nucleic acid sequence enhances the lytic activity of the bacteriophage. In some embodiments, replacement of non-essential and / or lysogenic genes with nucleic acid sequences confers lytic properties to the lysogenic bacteriophage.
[0172] In some embodiments, a nucleic acid sequence is introduced into a bacteriophage genome at a first location, while one or more non-essential and / or lysogenic genes are separately removed and / or inactivated from the bacteriophage genome at separate locations. In some embodiments, a nucleic acid sequence is introduced into a bacteriophage at a first location, while one or more non-essential and / or lysogenic genes are separately removed and / or inactivated from the bacteriophage genome at multiple separate locations. In some embodiments, the removal and / or inactivation of one or more non-essential and / or lysogenic genes does not affect the lytic activity of the bacteriophage. In some embodiments, the removal and / or inactivation of one or more non-essential and / or lysogenic genes preserves the lytic activity of the bacteriophage. In some embodiments, the removal of one or more non-essential and / or lysogenic genes renders a lysogenic bacteriophage a lytic bacteriophage.
[0173] In some embodiments, the bacteriophage is a temperate bacteriophage that has been rendered lytic by any of the aforementioned means. In some embodiments, the temperate bacteriophage is rendered lytic by the removal, replacement, or inactivation of one or more genes. In some embodiments, the lytic activity of the bacteriophage results from the removal, replacement, or inactivation of at least one lysogenic gene. In some embodiments, the lysogenic gene plays a role in maintaining the lysogenic cycle in the bacteriophage. In some embodiments, the lysogenic gene plays a role in establishing the lysogenic cycle in the bacteriophage. In some embodiments, the lysogenic gene plays a role in both establishing and maintaining the lysogenic cycle in the bacteriophage. In some embodiments, the lysogenic gene is a repressor gene. In some embodiments, the lysogenic gene is a cI repressor gene. In some embodiments, the lysogenic gene is an activator gene. In some embodiments, the lysogenic gene is a cII gene. In some embodiments, the lysogenic gene is a lexA gene. In some embodiments, the lysogenic gene is an int (integrase) gene. In some embodiments, two or more lysogenic genes are removed, replaced, or inactivated to result in the prevention of the bacteriophage lysogenization cycle and / or induction of the lytic cycle. In some embodiments, a temperate bacteriophage is rendered lytic by the insertion of one or more lytic genes. In some embodiments, a temperate bacteriophage is rendered lytic by the insertion of one or more genes that contribute to the induction of the lytic cycle. In some embodiments, a temperate bacteriophage is rendered lytic by modifying the expression of one or more genes that contribute to the induction of the lytic cycle. In some embodiments, a temperate bacteriophage is phenotypically changed from a temperate bacteriophage to a lytic bacteriophage. In some embodiments, a temperate bacteriophage is rendered lytic by modifying the environment.In some embodiments, environmental modifications include, but are not limited to, temperature, pH, or nutrient modifications, exposure to antibiotics, hydrogen peroxide, exogenous DNA, or DNA-damaging agents, the presence of organic carbon, and heavy metals (e.g., in the form of chromium(VI)). In some embodiments, the lysogenic bacteriophage that is rendered lytic is prevented from reverting to a lysogenic state. In some embodiments, the lysogenic bacteriophage that is rendered lytic is prevented from reverting to a lysogenic state by the self-targeting activity of the initially introduced CRISPR array. In some embodiments, the lysogenic bacteriophage that is rendered lytic is prevented from reverting to a lysogenic state by the introduction of an additional CRISPR array. In some embodiments, the bacteriophage does not confer any additional properties on the Pseudomonas species beyond causing cell death due to the lytic activity of the bacteriophage and / or the activity of the first or second CRISPR array.
[0174] In some embodiments, replacement, excision, inactivation, or any combination thereof, of one or more non-essential and / or lysogenic genes is achieved by chemical, biochemical, and / or any suitable method, hi some embodiments, insertion of one or more lytic genes is achieved by any suitable chemical, biochemical, and / or physical method by homologous recombination.
[0175] Nonessential genes In some embodiments, the non-essential genes to be removed and / or replaced from the bacteriophage are genes that are not essential for the viability of the bacteriophage, hi some embodiments, the non-essential genes to be removed and / or replaced from the bacteriophage are genes that are not essential for the induction and / or maintenance of the lytic cycle.
[0176] transcription activator In some embodiments, the nucleic acid sequence further comprises a transcriptional activator. In some embodiments, the encoded transcriptional activator regulates expression of a gene of interest in Pseudomonas species. In some embodiments, the transcriptional activator activates expression of a gene of interest in Pseudomonas species, whether exogenous or endogenous. In some embodiments, the transcriptional activator activates an expressed gene of interest in the target bacterium by interfering with the activity of one or more inhibitory elements in the target bacterium. In some embodiments, the inhibitory element comprises a transcriptional repressor. In some embodiments, the inhibitory element comprises a global transcriptional repressor. In some embodiments, the inhibitory element is a histone-like nucleoid structure (H-NS) protein or a homolog or functional fragment thereof. In some embodiments, the inhibitory element is a leucine-responsive regulatory protein (LRP). In some embodiments, the inhibitory element is a CodY protein.
[0177] In some bacteria, the CRISPR-Cas system is poorly expressed and considered inactive under most environmental conditions. In these bacteria, regulation of the CRISPR-Cas system is the result of the activity of transcriptional regulators, such as histone-like nucleoid structure (H-NS) proteins, which are widely involved in regulating host genome transcription. H-NS controls host transcriptional regulation by multimerizing along AT-rich sites, which results in DNA bending. In some bacteria, regulation of the CRISPR-Cas3 operon is regulated by H-NS.
[0178] Similarly, in some bacteria, repression of CRISPR-Cas systems is controlled by inhibitory elements, such as the leucine-responsive regulatory protein (LRP). LRPs are involved in binding to regions upstream and downstream of the transcription start site. Notably, the activity of LRPs in regulating the expression of CRISPR-Cas systems varies among bacteria. Unlike H-NS, which has broad interspecies repression activity, LRPs have been shown to differentially regulate the expression of host CRISPR-Cas systems. Thus, in some instances, LRPs represent a host-specific means of regulating CRISPR-Cas system expression in different bacteria.
[0179] In some instances, repression of CRISPR-Cas systems is also controlled by the inhibitory element CodY. CodY is a GTP-sensing transcriptional repressor that acts through DNA binding. The intracellular concentration of GTP acts as an indicator of environmental nutrient status. Under normal culture conditions, GTP is abundant and binds to CodY to repress transcriptional activity. However, when GTP concentrations decrease, CodY becomes less active in binding DNA, thereby allowing transcription of previously repressed genes. Thus, CodY acts as a strict, global transcriptional repressor.
[0180] In some embodiments, the transcriptional activator is a LeuO polypeptide, any homolog or functional fragment thereof, a LeuO coding sequence, or a drug that upregulates LeuO. In some embodiments, the transcriptional activator includes any ortholog or functional equivalent of LeuO. In some bacteria, LeuO acts in opposition to H-NS by acting as a global transcriptional regulator that responds to the nutritional status of the bacterial environment. Under normal conditions, LeuO expression is low. However, upon amino acid starvation and / or reaching stationary phase in the bacterial life cycle, LeuO is upregulated. Increased expression of LeuO antagonizes H-NS at overlapping promoter regions, achieving gene expression. Overexpression of LeuO upregulates the expression of CRISPR-Cas systems.
[0181] In some embodiments, expression of LeuO results in the destruction of an inhibitory element. In some embodiments, the destruction of the inhibitory element due to expression of LeuO removes transcriptional repression of the CRISPR-Cas system. In some embodiments, the expression of LeuO removes transcriptional repression of the CRISPR-Cas system due to the activity of H-NS. In some embodiments, the destruction of the inhibitory element due to expression of LeuO results in increased expression of the CRISPR-Cas system. In some embodiments, the increased expression of the CRISPR-Cas system due to the destruction of the inhibitory element due to expression of LeuO results in increased CRISPR-Cas processing of a nucleic acid sequence comprising a CRISPR array. In some embodiments, the increased expression of the CRISPR-Cas system due to the destruction of the inhibitory element due to expression of LeuO results in increased CRISPR-Cas processing of a nucleic acid sequence comprising a CRISPR array, thereby increasing the level of lethality of the CRISPR array against bacteria. In some embodiments, the transcriptional activator results in increased activity of a bacteriophage and / or a CRISPR-Cas system.
[0182] Adjustment element In some embodiments, the nucleic acid sequence is operably associated with various promoters, terminators, and other regulatory elements for expression in various organisms or cells. In some embodiments, the nucleic acid sequence further comprises a leader sequence. In some embodiments, the nucleic acid sequence further comprises a promoter sequence. In some embodiments, at least one promoter and / or terminator is operably linked to a CRISPR array. Any promoter useful in the present disclosure may be used, including, for example, a promoter functional for the organism of interest, as well as the constitutive, inducible, developmentally regulated, tissue-specific / preferred promoters disclosed herein. Regulatory elements used herein are endogenous or heterologous. In some embodiments, endogenous regulatory elements from a subject organism are inserted into a genetic context in which they do not naturally occur (e.g., a genomic location different from that found in nature), thereby producing a recombinant or non-naturally occurring nucleic acid.
[0183] In some embodiments, expression of the nucleic acid sequence is constitutive, inducible, temporally regulated, developmentally regulated, or chemically regulated. In some embodiments, expression of the nucleic acid sequence is made constitutive, inducible, temporally regulated, developmentally regulated, or chemically regulated by operably linking the nucleic acid sequence to a functional promoter in the organism of interest. In some embodiments, repression is made reversible by operably linking the nucleic acid sequence to an inducible promoter that is functional in the organism of interest. The selection of promoters disclosed herein will vary depending on the quantity, temporal, and spatial requirements for expression, as well as the host cell to be transformed.
[0184] Exemplary promoters for use with the methods, bacteriophages, and compositions disclosed herein include promoters that are functional in bacteria, such as the L-arabinose inducible (araBAD, PBAD) promoter, any lac promoter, the L-rhamnose inducible (rhaPBAD) promoter, the T7 RNA polymerase promoter, the trc promoter, the tac promoter, the lambda phage promoter (pLpL-9G-50), the anhydrotetracycline-inducible (tetA) promoter, trp, Ipp, phoA, recA, proU, cst-1, cadA, nar, Ipp-lac, cspA, the 11-lac operator, the T3-lac operator, the T4 gene 32, the T5-lac operator, the nprM-lac operator, Vhb, protein A, corynebacterial E. coli-like promoter, thr, horn, the diphtheria toxin promoter, sig A, sig B, and the like. B, nusG, SoxS, katb, α-amylase (Pamy), Ptms, P43 (composed of two overlapping RNA polymerase σ factor recognition sites, σA and σB), Ptms, P43, rplK-rplA, ferredoxin promoter, and / or xylose promoter. In some embodiments, the promoter is the BBa_J23102 promoter. In some embodiments, the promoter operates in a wide range of bacteria, such as BBa_J23104 or BBa_J23109. In some embodiments, the promoter is derived from the target bacterium, such as an endogenous CRISPR promoter, an endogenous Cas operon promoter, p16, plpp, or ptat. In some embodiments, the promoter is a phage promoter, such as the gp105 or gp245 promoter.
[0185] In some embodiments, the promoter comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises at least or about 95% homology to any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises at least or about 97% homology to any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises at least or about 99% homology to any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises 100% homology to any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises at least a portion having at least or about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more than 50 nucleotides of any one of SEQ ID NOs: 1-11. In some examples, the promoter comprises at least a portion having at least or about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, or more than 215 nucleotides of any one of SEQ ID NOs: 1-11.
[0186] In some embodiments, an inducible polymer is used. In some embodiments, a chemically-regulated promoter is used to regulate gene expression in an organism through the application of an exogenous chemical regulator. The use of a chemically-regulated promoter allows RNA and / or polypeptides encoded by a nucleic acid sequence to be synthesized only when the organism is treated, for example, with an inducing chemical. In some embodiments where a chemically-inducible promoter is used, gene expression is induced by application of the chemical. In some embodiments where a chemically-repressible promoter is used, gene expression is repressed by application of the chemical. In some embodiments, the promoter is a photoinducible promoter, such that gene expression is induced by application of light of a particular wavelength. In some embodiments, the promoter is a photorepressible promoter, such that gene expression is repressed by application of light of a particular wavelength.
[0187] Expression cassette In some embodiments, the nucleic acid sequence is or is in an expression cassette. In some embodiments, the expression cassette is designed to express a nucleic acid sequence disclosed herein. In some embodiments, the nucleic acid sequence is an expression cassette encoding components of a CRISPR-Cas system. In some embodiments, the nucleic acid sequence is an expression cassette encoding components of a type I CRISPR-Cas system. In some embodiments, the nucleic acid sequence is an expression cassette encoding an operable CRISPR-Cas system. In some embodiments, the nucleic acid sequence is an expression cassette encoding operable components of a type I CRISPR-Cas system, including cascade and Cas3. In some embodiments, the nucleic acid sequence is an expression cassette encoding operable components of a type I CRISPR-Cas system, including crRNA, cascade, and Cas3.
[0188] In some embodiments, the expression cassette containing the nucleic acid sequence of interest is chimeric, meaning that at least one of its components is heterologous to at least one of the other components, hi some embodiments, the expression cassette occurs naturally but has been obtained in a recombinant form useful for heterologous expression.
[0189] In some embodiments, the expression cassette comprises a transcriptional and / or translational termination region (i.e., a termination region) that is functional in a selected host cell. In some embodiments, the termination region contributes to the end of transcription beyond the heterologous nucleic acid sequence of interest and accurate mRNA polyadenylation. In some embodiments, the termination region is native to the transcriptional initiation region, native to the operably linked nucleic acid sequence of interest, native to the host cell, or obtained from another source (i.e., exogenous or heterologous to the promoter, nucleic acid sequence of interest, host, or any combination thereof). In some embodiments, a terminator is operably linked to a nucleic acid sequence disclosed herein.
[0190] In some embodiments, the expression cassette comprises a nucleotide sequence for a selectable marker, which in some embodiments encodes either a selectable or a screenable marker, depending on whether the marker confers a trait that is selected for by chemical means, such as using a selective agent (e.g., an antibiotic), or whether the marker is simply a trait that is identified through observation or examination, such as by screening (e.g., fluorescence).
[0191] vector In addition to expression cassettes, the nucleic acid sequences disclosed herein (e.g., nucleic acid sequences comprising CRISPR arrays) are used in conjunction with vectors. A vector comprises a nucleic acid molecule comprising a nucleotide sequence to be transcribed, delivered, or introduced. Non-limiting examples of general categories of vectors include, but are not limited to, viral vectors, plasmid vectors, phage vectors, phagemid vectors, cosmid vectors, fosmid vectors, bacteriophages, artificial chromosomes, or Agrobacterium binary vectors, which may or may not be self-transmissible, double-stranded, or single-stranded, in linear or circular form. Vectors transform prokaryotic or eukaryotic hosts either by integration into the cellular genome or by extrachromosomal existence (e.g., as an autonomously replicating plasmid with an origin of replication). Additionally, shuttle vectors are included, which refer to DNA vehicles that are naturally or by design capable of replicating in two different host organisms. In some embodiments, shuttle vectors replicate in actinomycetes as well as bacteria and / or eukaryotes. In some embodiments, the nucleic acid in the vector is under the control of, and operably linked to, a promoter or other regulatory elements suitable for transcription in a host cell, hi some embodiments, the vector is a bifunctional expression vector that functions in multiple hosts.
[0192] Codon optimization In some embodiments, the nucleic acid sequence is codon optimized for expression in any species of interest. Codon optimization involves modifying the nucleotide sequence for codon usage bias using a species-specific codon usage table. The codon usage table is generated based on sequence analysis of the most highly expressed genes in the species of interest. If the nucleotide sequence is expressed in the nucleus, the codon usage table is generated based on sequence analysis of highly expressed nuclear genes in the species of interest. Modifications of the nucleotide sequence are determined by comparing the species-specific codon usage table with the codons present in the native polynucleotide sequence. Codon optimization of a nucleotide sequence can result in a nucleotide sequence that has less than 100% identity (e.g., 50%, 60%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, etc.) to a native nucleotide sequence, yet still encodes a polypeptide with the same function as that encoded by the original nucleotide sequence. In some embodiments, the nucleic acid sequences of the present disclosure are codon optimized for expression in an organism / species of interest.
[0193] transformation In some embodiments, the nucleic acid sequences and / or expression cassettes disclosed herein are transiently expressed and / or stably integrated into the genome of a host organism. In some embodiments, the nucleic acid sequences and / or expression cassettes disclosed herein are introduced into cells by any method known to those of skill in the art. Exemplary methods of transformation include electroporation-mediated transformation of competent cells, passive uptake by competent cells, chemical transformation of competent cells, and any other electrical, chemical, physical (mechanical), and / or biological mechanism that results in the introduction of nucleic acids into cells, including any combination thereof. In some embodiments, transformation of cells comprises nuclear transformation. In some embodiments, transformation of cells comprises plasmid transformation and conjugation.
[0194] In some embodiments, when more than one nucleic acid sequence is introduced, the nucleotide sequences are located on the same or different nucleic acids, either as part of a single nucleic acid construct or assembled as separate nucleic acid constructs, hi some embodiments, the nucleotide sequences are introduced into the cell of interest in a single transformation event or in separate transformation events.
[0195] Antimicrobials and peptides In some embodiments, the bacteriophage disclosed herein are further genetically modified to express an antimicrobial peptide, a functional fragment of an antimicrobial peptide, or a lytic gene. In some embodiments, the bacteriophage disclosed herein expresses at least one antimicrobial agent or peptide disclosed herein. In some embodiments, the bacteriophage disclosed herein comprises a nucleic acid sequence encoding an enzybiotic whose protein product targets phage-resistant bacteria. In some embodiments, the bacteriophage comprises a nucleic acid encoding an enzyme that assists in the disruption or degradation of the biofilm matrix. In some embodiments, a bacteriophage disclosed herein comprises a nucleic acid encoding dispersin D aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenol oxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, or lyase. In some embodiments, the enzyme is selected from the group consisting of cellulases, such as the glycosyl hydroxylase family of cellulases, such as the glycosyl hydroxylase 5 family of enzymes, also known as cellulase A, polyglucosamine (PGA) depolymerase, and colanic acid depolymerase, such as 1,4-L-fucodise hydrolase, colanic acid, depolymerizing arginase, DNase I, or a combination thereof. In some embodiments, the bacteriophage disclosed herein secrete an enzyme disclosed herein.
[0196] In some embodiments, antimicrobial agents or peptides are expressed and / or secreted by the bacteriophage disclosed herein. In some embodiments, the bacteriophage disclosed herein secrete and express an antibiotic such as ampicillin, penicillin, penicillin derivatives, cephalosporins, monobactams, carbapenems, ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, norfloxacin, lomefloxacin, trovafloxacin, moxifloxacin, sparfloxacin, gemifloxacin, pazufloxacin, or any antibiotic disclosed herein. In some embodiments, the bacteriophage disclosed herein contain a nucleic acid sequence encoding an antimicrobial peptide, express an antimicrobial peptide, or secrete a peptide that assists or enhances killing of Pseudomonas species. In some embodiments, the bacteriophage disclosed herein comprises a nucleic acid sequence encoding a peptide, a nucleic acid sequence encoding an antimicrobial peptide, expresses an antimicrobial peptide, or secretes a peptide that supports or enhances the activity of the first and / or second Type I CRISPR-Cas system.
[0197] How to use In certain embodiments, disclosed herein are methods of killing Pseudomonas species, the methods comprising introducing any of the bacteriophages disclosed herein into the Pseudomonas species.
[0198] Further, in certain embodiments herein, disclosed is a method of modifying a mixed population of bacterial cells having a first bacterial species that contains a target nucleotide sequence in an essential gene and a second bacterial species that does not contain the target nucleotide sequence in an essential gene, the method comprising introducing any of the bacteriophages disclosed herein into the mixed population of bacterial cells.
[0199] Also disclosed in certain embodiments herein is a method of treating a disease or condition in an individual in need thereof, the method comprising administering to the individual any of the bacteriophages disclosed herein.
[0200] In some embodiments, Pseudomonas species are killed solely by the lytic activity of bacteriophage.In some embodiments, Pseudomonas species are killed solely by the activity of CRISPR-Cas system.In some embodiments, Pseudomonas species are killed by processing CRISPR arrays with CRISPR-Cas system to produce processed crRNA that can be targeted for CRISPR-Cas-based endonuclease activity and / or cleavage at target nucleotide sequences in bacterial target genes.
[0201] In some embodiments, Pseudomonas species are killed by a combination of the lytic activity of the bacteriophage and the activity of the type I CRISPR-Cas system. In some embodiments, Pseudomonas species are killed by the activity of the type I CRISPR-Cas system independently of the lytic activity of the bacteriophage. In some embodiments, the activity of the type I CRISPR-Cas system complements or enhances the lytic activity of the bacteriophage. In some embodiments, the activity of the type I CRISPR-Cas system and the lytic activity of the bacteriophage are additive.
[0202] In some embodiments, the lytic activity of the bacteriophage and the activity of the type I CRISPR-Cas system are synergistic. In some embodiments, synergistic activity is defined as activ...
Claims
1. (a) a CRISPR array comprising one or more spacer sequences complementary to a target nucleotide sequence in Pseudomonas species; (b) a cascade polypeptide; and (c) a Cas3 polypeptide; A bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system comprising:
2. The CRISPR array comprises: (a) a promoter sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 1 to 11, and / or (b) a spacer sequence having at least 90% identity to any one of SEQ ID NOs: 88-116 or 31-74. The bacteriophage of claim 1 , comprising:
3. A bacteriophage composition comprising the bacteriophage of claim 1 or claim 2, further comprising a p1695wt bacteriophage and / or a p4430wt bacteriophage.
4. A bacteriophage described in claim 1 or claim 2, wherein the cascade polypeptide forms a cascade complex of a type I-C CRISPR-Cas system, a type I-B CRISPR-Cas system, a type I-A CRISPR-Cas system, a type I-D CRISPR-Cas system, a type I-E CRISPR-Cas system, or a type I-F CRISPR-Cas system.
5. The cascade complex comprises: (i) Cas5d polypeptide, Cas8c polypeptide, and Cas7 polypeptide (IC type CRISPR-Cas system); (ii) Cas6b polypeptide, Cas8b polypeptide, Cas7 polypeptide, and Cas5 polypeptide (I-B type CRISPR-Cas system); (iii) Cas7 polypeptide, Cas8a1 polypeptide or Cas8a2 polypeptide, Cas5 polypeptide, Csa5 polypeptide, and Cas6a polypeptide, wherein the Cas3 polypeptide comprises a Cas3′ polypeptide and a Cas3″ polypeptide that do not have nuclease activity (Type I-A CRISPR-Cas system); (iv) Cas10d polypeptide, Csc2 polypeptide, Csc1 polypeptide, Cas6d polypeptide (ID type CRISPR-Cas system), (v) a Cse1 polypeptide, a Cse2 polypeptide, a Cas7 polypeptide, a Cas5 polypeptide, and a Cas6e polypeptide (type I-E CRISPR-Cas system), or (vi) Csy1 polypeptide, Csy2 polypeptide, Csy3 polypeptide, and Csy4 polypeptide (IF type CRISPR-Cas system) Contains or 3. The bacteriophage of claim 1 or claim 2, wherein the Cascade complex comprises a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (Type I-C CRISPR-Cas system).
6. A bacteriophage described in claim 1 or claim 2, wherein the Cas3 polypeptide comprises an sequence that is at least about 90% identical to sequence number 79. (a) a modified p1106, p1835, p1772, or p2131 phage, (b) infected with multiple bacterial strains of said Pseudomonas species; and / or (c) PhiKZ virus, PhiKMV virus, Brunyoghe virus, Samuna virus, Nankoku virus, Abidjan virus, Baikal virus, Beetre virus, Casadaban virus, Citex virus, Cysto virus, Detre virus, El virus, Holloway virus, Kochitakasu virus, Lituna virus, Luzseptima 3. The bacteriophage of claim 1 or claim 2, comprising a virus, Nipuna virus, Pakpuna virus, Pamex virus, Paundecim virus, Phitre virus, Primolici virus, Septimatre virus, Stubbur virus, Tertilici virus, Yua virus, Zicotria virus, or Pbuna virus, or a combination of two or more thereof.
8. A method for killing Pseudomonas species, comprising the step of introducing a nucleic acid sequence encoding a type I CRISPR-Cas system from a bacteriophage described in claim 1 or claim 2 into a target bacterium, wherein the target nucleotide sequence is present in the Pseudomonas species.
9. Use of a bacteriophage according to claim 1 or claim 2 in the manufacture of a medicament for treating a disease or illness in a subject in need of such treatment.
10. Use of a p1695wt bacteriophage and / or a p4430wt bacteriophage in the manufacture of a medicament for treating a disease or illness in a subject in need of such treatment.
11. The use described in claim 9 or claim 10, wherein the subject is infected with Pseudomonas species.
12. The use described in claim 9 or claim 10, wherein the disease or illness is a bacterial infection.
13. The use of claim 12, wherein the bacterial infection is associated with cystic fibrosis or non-cystic fibrosis bronchiectasis.
14. The method of claim 1, wherein the Pseudomonas species (a) drug-resistant Pseudomonas species; (b) multidrug-resistant Pseudomonas spp.; (c) Pseudomonas aeruginosa, and / or (d) killed by the lytic activity of the bacteriophage and / or the activity of the CRISPR-Cas system; The method according to claim 8 or the use according to claim 11.
15. The method or use of claim 14, wherein the drug-resistant Pseudomonas species is resistant to at least one antibiotic.
16. The method or use of claim 14, wherein the multidrug-resistant Pseudomonas species is resistant to at least one antibiotic.
17. The method or use of claim 15 or claim 16, wherein the antibiotic comprises a cephalosporin, a fluoroquinolone, a carbapenem, colistin, an aminoglycoside, vancomycin, streptomycin, or methicillin.
18. The method of claim 8 or the use of claim 9 or 11, wherein the bacteriophage is an obligately lytic bacteriophage or a lysogenic bacteriophage that has been given lytic properties.
19. The method or use described in claim 14 or 18, wherein the lytic activity of the bacteriophage and the activity of the CRISPR-Cas system are synergistic.
20. A nucleic acid comprising SEQ ID NO:83, or a sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
83.
21. A nucleic acid comprising SEQ ID NO:25, or a sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
25.
22. A bacteriophage comprising the nucleic acid described in claim 20 or claim 21.
23. A bacteriophage having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to p1106e003, p1772e005, p1835e002, p2131e002, or two or more phages thereof, wherein the bacteriophage is a recombinant bacteriophage.
24. (a) a CRISPR array; and (b) a cascade polypeptide comprising one or more spacer sequences complementary to one or more target nucleotide sequences in Pseudomonas species; (c) a Cas3 polypeptide; 24. The bacteriophage of claim 22 or claim 23, comprising:
25. The bacteriophage described in claim 24, wherein the one or more spacer sequences include at least one of SEQ ID NOs: 12, 16 and 20.
26. A method for producing a nucleic acid sequence comprising: (a) a CRISPR array comprising one or more spacer sequences complementary to one or more target nucleotide sequences in Pseudomonas species, wherein the one or more spacer sequences comprise at least one of SEQ ID NOs: 12, 16, and 20; and (b) a cascade polypeptide; and (c) a Cas3 polypeptide; A bacteriophage comprising a nucleic acid sequence encoding a type I CRISPR-Cas system comprising:
27. The CRISPR array, (a) SEQ ID NO: 12, (b) SEQ ID NO: 16, and / or (c) SEQ ID NO: 20, and / or (d) a promoter sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 1 to 11.
27. The bacteriophage of claim 25 or claim 26, comprising:
28. A bacteriophage described in any one of claims 24 to 27, wherein the cascade polypeptide forms a cascade complex of a type I-C CRISPR-Cas system, a type I-B CRISPR-Cas system, a type I-A CRISPR-Cas system, a type I-D CRISPR-Cas system, a type I-E CRISPR-Cas system, or a type I-F CRISPR-Cas system.
29. The cascade complex comprising: (i) Cas5d polypeptide, Cas8c polypeptide, and Cas7 polypeptide (IC type CRISPR-Cas system); (ii) Cas6b polypeptide, Cas8b polypeptide, Cas7 polypeptide, and Cas5 polypeptide (I-B type CRISPR-Cas system); (iii) Cas7 polypeptide, Cas8a1 polypeptide or Cas8a2 polypeptide, Cas5 polypeptide, Csa5 polypeptide, and Cas6a polypeptide, wherein the Cas3 polypeptide comprises a Cas3′ polypeptide and a Cas3″ polypeptide that do not have nuclease activity (Type I-A CRISPR-Cas system); (iv) Cas10d polypeptide, Csc2 polypeptide, Csc1 polypeptide, Cas6d polypeptide (ID type CRISPR-Cas system), (v) a Cse1 polypeptide, a Cse2 polypeptide, a Cas7 polypeptide, a Cas5 polypeptide, and a Cas6e polypeptide (type I-E CRISPR-Cas system), or (vi) a Csy1 polypeptide, a Csy2 polypeptide, a Csy3 polypeptide, and a Csy4 polypeptide (type I-F CRISPR-Cas system); or (vi) a Cas5d polypeptide (optionally SEQ ID NO: 80), a Cas8c polypeptide (optionally SEQ ID NO: 81), and a Cas7 polypeptide (optionally SEQ ID NO: 82) (type I-C CRISPR-Cas system).
29. The bacteriophage of claim 28, comprising:
30. A bacteriophage according to any one of claims 22 to 29, comprising SEQ ID NO:83, or a sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
83.
31. A bacteriophage according to any one of claims 22 to 30, comprising SEQ ID NO:25, or a sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
25.
32. A bacteriophage described in any one of claims 22 to 31, comprising at least 85% or 90% identity to p1106e003, p1772e005, p1835e002, p2131e002, or two or more phages thereof.
33. (a) a first bacteriophage comprising at least 80% sequence identity to p1106e003; and (b) a second bacteriophage that contains at least 80% sequence identity to p1835e002; and (c) a third bacteriophage comprising at least 80% sequence identity to p1772e005; and (d) a fourth bacteriophage comprising at least 80% sequence identity to p2131e002; and 33. The bacteriophage of any one of claims 22 to 32, comprising: (a) at least 80% sequence identity to p1695; or (b) contains at least 80% sequence identity to p4430; 34. The bacteriophage of claim 33, further comprising a fifth bacteriophage.
35. The bacteriophage of claim 34, further comprising a sixth bacteriophage having at least 80% sequence identity to p1695.
36. A method for killing a Pseudomonas target bacterium, comprising the step of administering a nucleic acid described in claim 20 or claim 21, or a bacteriophage described in any one of claims 22 to 35, to a subject requiring killing of the Pseudomonas target bacterium.
37. Use of a nucleic acid according to claim 20 or claim 21 or a bacteriophage according to any one of claims 22 to 35 in the manufacture of a medicament for treating a disease or illness in a subject in need of such treatment.
